

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 December 2011 (29.12.2011)

(10) International Publication Number  
**WO 2011/161124 A1**

(51) International Patent Classification:

*C07K 14/62 (2006.01)*

(21) International Application Number:

PCT/EP2011/060382

(22) International Filing Date:

21 June 2011 (21.06.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10167033.9 23 June 2010 (23.06.2010) EP  
61/359,500 29 June 2010 (29.06.2010) US

(71) Applicant (for all designated States except US): **NOVO NORDISK A/S** [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LUDVIGSEN, Svend** [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). **HUBALEK, Frantisek** [CZ/DK]; Novo Allé, DK-2880 Bagsværd (DK). **KJELDSEN, Thomas Børglum** [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



**WO 2011/161124 A1**

---

(54) Title: INSULIN ANALOGUES CONTAINING ADDITIONAL DISULFIDE BONDS

(57) Abstract: The present invention is related to insulin analogues containing additional disulfide bonds and methods of making such.

## INSULIN ANALOGUES CONTAINING ADDITIONAL DISULFIDE BONDS

### FIELD OF THE INVENTION

The present invention is related to insulin analogues containing additional disulfide bonds and methods of making such.

### BACKGROUND OF THE INVENTION

Diabetes mellitus is a metabolic disorder in which the ability to utilize glucose is partly or completely lost. In the treatment of diabetes mellitus, many varieties of insulin formulations have been suggested and used, such as regular insulin, isophane insulin (designated NPH), insulin zinc suspensions (such as Semilente<sup>®</sup>, Lente<sup>®</sup>, and Ultralente<sup>®</sup>), and biphasic isophane insulin.

Human insulin consists of two polypeptide chains, the A and B chains which contain 21 and 30 amino acid residues, respectively. The A and B chains are interconnected by two disulfide bridges. Insulin from most other species is similar, but may contain amino acid substitutions in some positions. Within the last decade a number of human insulin analogues have been developed. They are designed for particular profiles of action, i.e. fast acting or prolonged action. Commercially available products comprising such insulin analogues include Levemir<sup>®</sup>, NovoRapid<sup>®</sup>, Humalog<sup>®</sup>, Apidra<sup>®</sup> and Lantus<sup>®</sup>.

Human insulin is rapidly degraded in the lumen of gastrointestinal tract by the action of multiple proteases limiting its absorption into circulation. Insulin analogues that are hydrophilic and stabilized towards proteolytic degradation show higher bioavailability in animal models when compared to native insulin.

Incorporation of disulfide bonds into proteins is one of nature's ways of improving protein stability; a correlation between the abundance of disulfide bonds and the maximum growth temperature among thermophilic organisms has been found, implicating the importance of disulfide bonds in protein stabilization in high temperature environments (Mallick P, et al, 2002, Proc. Natl. Acad. Sci. USA, 99, 9679-9684.; Ladenstein R, et al, 2006, FEBS J., 273, 4170-4185). There are also many examples of disulfide bonds being successfully engineered into proteins with concomitant increases in stability. One of the largest stabilizations was achieved for RNase barnase (upto 4.1 kcal mol<sup>-1</sup> depending on the position of the new disulfide bond) (Clarke J., Fersht A., 1993, Biochem., 32, 4322-4329). Such stabilization is brought about by increasing the activation energy required for unfolding or by constraining the unfolded conformations of the protein and thereby decreasing their conformational en-

tropy (Pace C.N., 1990, Trends Biol. Sci., 14-17). However, much more needs to be learned in this emerging area of research. To date, there are no reports of engineered disulfide bonds in insulin.

There is still a need for novel insulin analogues which are stable.

## 5 SUMMARY OF THE INVENTION

The present invention is related to insulin analogues having two or more cysteine substitutions, and at least one amino acid residue which is substituted with an amino acid which is not a cysteine, where the three disulfide bonds of human insulin are retained, and the sites of cysteine substitutions are chosen in such a way that the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin.

In one aspect an insulin analogue of the invention is obtained, wherein the sites of cysteine substitutions are chosen in such a way that (1) the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin, and (2) the human insulin analogue retains the desired biological activities associated with human insulin.

In one aspect an insulin analogue of the invention is obtained, wherein the sites of cysteine substitutions are chosen in such a way that (1) the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin, (2) the human insulin analogue retains the desired biological activities associated with human insulin, and (3) the human insulin analogue has increased physical stability relative to human insulin and/or parent insulin

25 In one aspect an insulin analogue of the invention is obtained, wherein the sites of cysteine substitutions are chosen in such a way that (1) the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin, (2) the human insulin analogue retains the desired biological activities associated with human insulin, and (3) the human insulin analogue is stabilized against proteolytic degradation.

Herein is also described a method for stabilizing an insulin comprising substituting two or more amino acids of human insulin or desB30 human insulin with cysteine residues and at least one amino acid residue with an amino acid which is not a cysteine, wherein

- a. the three disulfide bonds of human insulin are retained and

- b. the sites of cysteine substitutions are chosen in such a way that the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin,
- 5 thereby creating an insulin analogue comprising one or more additional disulfide bonds not present in human insulin.

## DESCRIPTION OF THE DRAWINGS

**Figure 1.** Differential Scanning Calorimetry (DSC) comparison of human insulin and Example 60. The melting temperature of the insulin analogue of Example 60 was 35.1°C higher than that of human insulin.

**Figure 2.** ThT fibrillation assay comparison of human insulin and the insulin analogue of Example 55. Human insulin fibrillation was readily detected with a lag time of <2h, while the insulin analogue of Example 55 did not fibrillate within the 45h duration of the experiment.

**Figure 3.** Blood glucose profiles following i.v administration of human insulin (prior art) and the insulin analogue of Example 55 (panel A) and the insulin analogue of Example 60 (panel B). Insulin analogues were administrated in 3.6 nmol/kg (mean values  $\pm$  SEM).

## 20 DESCRIPTION OF THE INVENTION

In the present invention novel insulin analogues are presented wherein disulfide bonds are engineered into the insulin analogue.

In one aspect an insulin analogue according to the invention has two or more cysteine substitutions and the three disulfide bonds of human insulin are retained.

25 In one aspect of the invention, the sites of cysteine substitutions are chosen in such a way that the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin.

It has by the inventors been found that the insulin analogues according to the invention have improved physical stability. It has thus been found that the tendency of the insulin analogues according to the invention to form biologically inactive and/or insoluble aggregates of the insulin analogues is reduced for example as a result of exposure of the analogues to

thermo-mechanical stresses and/or interaction with interfaces and surfaces that are destabilizing, such as hydrophobic surfaces and interfaces.

The insulin analogues according to the invention bind to the insulin receptor. It has thus surprisingly been found by the inventors that the insulin analogues according to the invention have both improved physical stability and retain binding to the insulin receptor.

In one aspect the insulin analogues of the invention are stabilized against proteolytic degradation, i.e. against rapid degradation in the gastro intestinal (GI) tract or elsewhere in the body. In one aspect the insulin analogues of the invention are stabilized against proteolytic degradation relative to the parent insulins.

An insulin analogue which is stabilized against proteolytic degradation is herein to be understood as an insulin analogue, which is subjected to slower degradation by one or more proteases relative to human insulin. In one embodiment an insulin analogue according to the invention is subjected to slower degradation by one or more proteases relative to human insulin. In a further embodiment of the invention an insulin analogue according to the invention is stabilized against degradation by one or more enzymes selected from the group consisting of: pepsin (such as e.g. the isoforms pepsin A, pepsin B, pepsin C and/or pepsin F), chymotrypsin (such as e.g. the isoforms chymotrypsin A, chymotrypsin B and/or chymotrypsin C), trypsin, Insulin-Degrading Enzyme (IDE), elastase (such as e.g. the isoforms pancreatic elastase I and/or II), carboxypeptidase (e.g. the isoforms carboxypeptidase A, carboxypeptidase A2 and/or carboxypeptidase B), aminopeptidase, cathepsin D and other enzymes present in intestinal extracts derived from rat, pig or human.

In one embodiment an insulin analogue according to the invention is stabilized against degradation by one or more enzymes selected from the group consisting of: chymotrypsin, trypsin, Insulin-Degrading Enzyme (IDE), elastase, carboxypeptidases, aminopeptidases and cathepsin D. In a further embodiment an insulin analogue according to the invention is stabilized against degradation by one or more enzymes selected from the group consisting of: chymotrypsin, carboxypeptidases and IDE. In a yet further embodiment an insulin analogue according to the invention is stabilized against degradation by one or more enzymes selected from: chymotrypsin and IDE. In a yet further embodiment an insulin analogue according to the invention is stabilized against degradation by one or more enzymes selected from: chymotrypsin and carboxypeptidases.

A "protease" or a "protease enzyme" is a digestive enzyme which degrades proteins and peptides and which is found in various tissues of the human body such as e.g. the stomach (pepsin), the intestinal lumen (chymotrypsin, trypsin, elastase, carboxypeptidases, etc.) or mucosal surfaces of the GI tract (aminopeptidases, carboxypeptidases, enteropeptidases,

dipeptidyl peptidases, endopeptidases, etc.), the liver (Insulin degrading enzyme, cathepsin D etc), and in other tissues.

T<sub>1/2</sub> may be determined as a measure of the proteolytical stability of an insulin analogue according to the invention towards protease enzymes such as chymotrypsin, pepsin and/or carboxypeptidase A or towards a mixture of enzymes such as tissue extracts (from liver, kidney, duodenum, jejunum, ileum, colon, stomach, etc.). In one embodiment of the invention T<sub>1/2</sub> is increased relative to human insulin. In a further embodiment T<sub>1/2</sub> is increased relative to the parent insulin. In a yet further embodiment T<sub>1/2</sub> is increased at least 2-fold relative to the parent insulin. In a yet further embodiment T<sub>1/2</sub> is increased at least 3-fold relative to the parent insulin. In a yet further embodiment T<sub>1/2</sub> is increased at least 4-fold relative to the parent insulin. In a yet further embodiment T<sub>1/2</sub> is increased at least 5-fold relative to the parent insulin. In a yet further embodiment T<sub>1/2</sub> is increased at least 10-fold relative to the parent insulin.

In one aspect, the insulin analogues according to the invention have improved chemical stability. In one aspect, the insulin analogues according to the invention have improved physical stability. In one aspect, the insulin analogues according to the invention have improved chemical and physical stability.

In one aspect, an insulin analogue according to the invention has improved chemical and/or physical stability relative to human insulin. In one aspect, an insulin analogue according to the invention has improved chemical and/or physical stability relative to the parent insulin.

The term "physical stability" as used herein refers to the tendency of the insulin analogue to form biologically inactive and/or insoluble aggregates of the insulin analogue as a result of exposure of the insulin analogue to thermo-mechanical stresses and/or interaction with interfaces and surfaces that are destabilizing, such as hydrophobic surfaces and interfaces. Physical instability thus involves conformational changes relative to human insulin, which includes loss of higher order structure, aggregation, fibrillation, precipitation and/or adsorption to surfaces. Peptides such as insulin are known to be prone to instability due to e.g. fibrillation. Physical stability of a solution comprising the insulin analogue may be evaluated by conventional means of e.g. visual inspection, nephelometry and/or turbidity measurements after exposing the solution filled in suitable containers (e.g. cartridges or vials) to mechanical/physical stress (e.g. agitation) at different temperatures for various time periods. Visual inspection of the solution is performed in a sharp focused light with a dark background. The turbidity of the solution is characterized by a visual score ranking the degree of turbidity for instance on a scale from 0 to 3 (a solution showing no turbidity corresponds to a

visual score 0, and a solution showing visual turbidity in daylight corresponds to visual score 3). A solution is classified physical unstable with respect to protein aggregation, when it shows visual turbidity in daylight. Alternatively, the turbidity of the solution can be evaluated by simple turbidity measurements well-known to the skilled person. Physical stability of the 5 insulin analogue can also be evaluated by using a spectroscopic agent or probe of the conformational status of the insulin analogue. The probe is preferably a small molecule that preferentially binds to a non-native conformer of the protein. One example of a small molecular spectroscopic probe of protein structure is Thioflavin T. Thioflavin T is a fluorescent dye that has been widely used for the detection of amyloid fibrils. In the presence of fibrils, and 10 perhaps other protein configurations as well, Thioflavin T gives rise to a new excitation maximum at about 450 nm and enhanced emission at about 482 nm when bound to a fibril protein form. Unbound Thioflavin T is essentially non-fluorescent at the wavelengths. Physical stability of the insulin analogues of the invention may e.g. be determined as described in example 90.

15 Other small molecules can be used as probes of the changes in protein structure from native to non-native states. For instance the "hydrophobic patch" probes that bind preferentially to exposed hydrophobic patches of a protein. The hydrophobic patches are generally buried within the tertiary structure of a protein in its native state, but become exposed as a protein begins to unfold or denature. Examples of these small molecular, spectroscopic 20 probes are aromatic, hydrophobic dyes, such as anthracene, acridine, phenanthroline or the like. Other spectroscopic probes are metal-amino acid complexes, such as cobalt metal complexes of hydrophobic amino acids, such as phenylalanine, leucine, isoleucine, methionine, and valine, or the like.

25 The term "chemical stability" of the insulin analogue as used herein refers to chemical covalent changes in the protein structure leading to formation of chemical degradation products with potential less biological potency and/or potential increased immunogenic properties compared to the native protein structure and involves avoidance of degradation of covalent bonds, such as hydrolysis, racemization, oxidation or crosslinking. Various chemical degradation products can be formed depending on the type and nature of the native protein 30 and the environment to which the insulin analogue is exposed. Elimination of chemical degradation can most probably not be completely avoided and increasing amounts of chemical degradation products is often seen during storage and use of the protein formulation as well-known by the person skilled in the art. Most proteins are prone to deamidation, a process in which the side chain amide group in glutamine or asparagine residues is hydrolysed to form 35 a free carboxylic acid. Asparagine and aspartic acid residues may further form isoAsp degra-

dation products. Other degradations pathways involves formation of high molecular weight transformation products where two or more protein molecules are covalently bound to each other through transamidation and/or disulfide interactions leading to formation of covalently bound dimer, oligomer and polymer degradation products (Stability of Protein Pharmaceuticals, Ahern. T.J. & Manning M.C., Plenum Press, New York 1992). Oxidation (of for instance methionine residues) and racemization can be mentioned as another variant of chemical degradation. The chemical stability of the insulin analogue can be evaluated by measuring the amount of the chemical degradation products at various time-points after exposure to different environmental conditions (the formation of degradation products can often be accelerated by for instance increasing temperature). The individual degradation products are often determined by separation of the degradation products depending on molecule size and/or charge e.g. using a combination of chromatographic (e.g. SEC-HPLC, RP-HPLC or IE-HPLC) and spectroscopic methods (various mass spectrometry methods) sometimes in combinations with chemical/enzymatic fragmentation.

15 In one embodiment, the insulin analogue of the invention has improved chemical stability relatively to that of human insulin and/or parent insulin when tested as described in the examples.

20 In one embodiment, the insulin analogue of the invention has increased hydrophilicity relative to that of human insulin and/or the parent insulin when tested for hydrophobicity as known by the skilled person and e.g. described in example 92.

In one embodiment, the insulin analogue of the invention has little or no tendency to aggregate. The aggregation tendency is preferably significantly improved relatively to the aggregation tendency of human insulin and/or parent insulin when tested in a thioflavin assay.

25 An insulin analogue according to the invention may have substantially the same or increased in vivo potency relative to the parent insulin. In one aspect an insulin analogue of the invention has substantially the same in vivo potency relative to the parent insulin. In one aspect an insulin analogue of the invention has increased in vivo potency relative to the parent insulin.

30 Standard assays for measuring insulin in vivo potency are known to the person skilled in the art and include assays described in the examples, such as; Potency of insulin analogues of the invention relative to human insulin, intravenous steady-state clamp assays such as rat pharmacokinetics and rat PK following intraintestinal injection, blood glucose lowering effect and intravenous rat PK assays..

35 An insulin analogue according to the invention may have substantially the same or increased in vitro potency relative to the parent insulin. In one aspect an insulin analogue of

the invention has substantially the same in vitro potency relative to the parent insulin. In one aspect an insulin analogue of the invention has increased in vitro potency relative to the parent insulin.

Standard assays for measuring insulin in vitro potency are known to the person

5 skilled in the art and include *inter alia* the below *in vitro* assays:

(1) insulin radioreceptorassays, in which the relative potency of an insulin is defined as the ratio of insulin to insulin analogue required to displace 50% of  $^{125}\text{I}$ -insulin specifically bound to insulin receptors present on cell membranes, e.g. a rat liver plasma membrane fraction;

(2) lipogenesis assays, performed e.g. with rat adipocytes, in which relative insulin potency is 10 defined as the ratio of insulin to insulin analogue required to achieve 50% of the maximum conversion of  $[3-^3\text{H}]$  glucose into organic-extractable material (i.e. lipids); and

(3) glucose oxidation assays in isolated fat cells in which the relative potency of the insulin analogue is defined as the ratio of insulin to insulin analogue to achieve 50% of the maximum conversion of glucose-1- $[^{14}\text{C}]$  into  $[^{14}\text{CO}_2]$ .

15 In one aspect, an insulin analogue according to the invention has improved thermodynamic stability such as e.g. folding stability, conformational stability and/or higher melting temperature.

When used herein an insulin analogue is said to have improved "thermodynamic stability" if denaturation of said analogue requires higher stress level such as higher 20 temperature and/or higher concentration of denaturation agent in comparison to human insulin or the parent insulin.

Conformational stability may be evaluated by circular dichroism and NMR as e.g. described by Hudson and Andersen, Peptide Science, vol 76 (4), pp. 298-308 (2004). Melting temperature is understood as the temperature at which an insulin structure is reversibly 25 or irreversibly changed. Higher melting temperature corresponds to more stable structures. Melting temperature can be determined e.g. by evaluating conformational stability by circular dichroism and/or NMR as a function of temperature or by differential scanning calorimetry. Thermodynamic stability can also be determined by CD spectroscopy and or NMR in the presence of increasing concentration of denaturation agent, such as for example guanidinium hydrochloride. Free energy of unfolding as described previously (Kaarsholm, N.C., et al., 1993, Biochemistry, 32, 10773-8) can be determined from such experiments. Upon protein 30 denaturation, negative CD in the far UV range (240-218-nm) gradually diminishes, consistent with the loss of ordered secondary structure that accompanies protein unfolding (Holladay et al., 1977, Biochim. Biophys. Acta, 494, 245-254; Melberg and Johnson, 1990, Biochim. Biophys. Acta, 494, 245-254). The insulin CD spectrum in the near UV range (330-250-nm) re-

flects the environment of the tyrosine chromophore with contributions from the disulfide bonds (Morris et al., 1968, *Biochim.Biophys. Acta.*, 160, 145-155; Wood et al., 1975, *Biochim. Biophys. Acta*, 160, 145-155; Strickland & Mercola, 1976, *Biochemistry*, 15, 3875-3884). The free energy of unfolding of insulin was previously calculated from such studies to 5 be 4.5 kcal/mol (Kaarsholm, N.C., et al, 1993, *Biochemistry*, 32, 10773-8).

Insulin CD spectrum in the near UV range (330-250-nm) reflects the environment of the tyrosine chromophore with contributions from the disulfide bonds. Since tyrosine residues are part of the insulin's dimer surface, changes in molar elipticity at this region (especially at 276 nm) reflect on insulin's association state. Another way to measure insulin's 10 association state is by application of size-exclusion chromatography under non-dissociating conditions as known in the art and described in the examples.

Disulfide bonds are derived by the coupling of two thiol groups and are herein to be understood as the linkage between two sulfur atoms, i.e. a structure having the overall connectivity R-S-S-R. Disulfide bonds may also be called connecting disulfide bonds, SS-bonds 15 or disulfide bridges. A disulfide bond is created by the introduction of two cysteine amino acid residues to a peptide with subsequent oxidation of the two thiol groups to a disulfide bond. Such oxidation can be performed chemically (as known by persons skilled in the art) or can happen during insulin expression in e.g. yeast.

When introducing cysteine residues into the parent insulin, the cysteine residues are 20 placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin. For example, if placing two new cysteine residues, the proximity of the new cysteine residues in the three dimensional structure is such that a disulfide bond can be formed between the two new cysteine residues.

25 The number of disulfide bonds in a protein (such as insulin) can be readily determined by accurate intact mass measurements as described, for example in the Examples. The disulfide bonds connectivity can be verified (determined) by standard techniques known in the art, such as peptide mapping. The general strategy for disulfide bond mapping in an insulin peptide includes the following steps: 1) Fragmentation of the non-reduced insulin into 30 disulfide bonded peptides containing, if possible, only a single disulfide bond per peptide. The chosen conditions is also such that rearrangement of disulfide bonds is avoided, 2) Separation of disulfide bonded peptides from each other. 3) Identification of the cysteine residues involved in the individual disulfide bonds.

Human insulin is typically digested by Glu-C protease yielding peptide I containing 35 two disulfide bonds (A6-A11 and A7- B7) and peptide II containing a single disulfide bond

(A20-B19). To unambiguously assign the disulfide bonds in peptide I, further fragmentation is necessary. Acid hydrolysis (Ryle et al., 1955 Biochem J. 60, 541-56), manual Edman degradation (Kumazaki T, Ishii, S. 1990 J. Biochem (Tokyo) 17, 414-9), or prolonged digestion with thermolysin (Ota M, Ariyoshi, Y., 1995, Biosci. Biotech. Biochem. 59, 1956-7) were 5 previously employed to hydrolyze CysCys bonds in proteins. An alternative way to assign the disulfide bonds in peptide I is a partial reduction with triscarboxyethyl phosphine (reduction of A7-B7 disulfide bond), alkylation of the reduced cysteine residues followed by complete reduction and cysteine alkylation using a different alkyl group (Yen, T.-Y., Yan, H., Macher, B., 2001 J Mass Spectrom. 37, 15-30). The strategy for disulfide mapping of insulins 10 containing extra disulfide bonds is in principle the same as outline above for human insulin adjusted for each analogue in such a way that accommodates the new disulfide bond. Determination of insulin structure by NMR or X-ray crystallography is an alternative approach for verifying the disulfide bond connectivity. Conditions for solving NMR and/or X-ray structures of insulin have been described previously and are known in the art.

15 In one aspect of the invention an insulin analogue which has at least two cysteine substitutions and at least one other amino acid residue substitution relative to human insulin or desB30 human insulin is provided, where the three disulfide bonds of human insulin are retained.

With the term "cysteine substitution" is herein meant replacing an amino acid which 20 is present in human insulin with a cysteine. For example, isoleucine in position 10 in the A chain (IleA10) and glutamine in position 4 of the B chain of human insulin (GlnB4) may each be replaced by a cysteine residue. With the term "other amino acid residue substitution" is herein meant replacing an amino acid which is present in human insulin with an amino acid which is not cysteine.

25 The term "human insulin" as used herein means the human insulin hormone whose two dimensional and three dimensional structure and properties are well-known. The three dimensional structure of human insulin has been e.g. determined by NMR and X-ray crystallography under many different conditions and many of these structures are deposited in the Protein data bank (<http://www.rcsb.org> ). Non-limiting examples of a human insulin structure 30 is the T6 structure (<http://www.rcsb.org/pdb/explore.do?structureId=1MSO>) and the R6 structure (<http://www.rcsb.org/pdb/explore.do?structureId=1EV3>). Human insulin has two polypeptide chains, named the A-chain and the B-chain. The A-chain is a 21 amino acid peptide and the B-chain is a 30 amino acid peptide, the two chains being connected by disulfide bonds: a first bridge between the cysteine in position 7 of the A-chain and the cysteine in position 7 of 35 the B-chain, and a second bridge between the cysteine in position 20 of the A-chain and the

cysteine in position 19 of the B-chain. A third bridge is present between the cysteines in position 6 and 11 of the A-chain. Thus, "an insulin analogue where the three disulfide bonds of human insulin are retained" is herein understood as an insulin analogue comprising the three disulfide bonds of human insulin, i.e. a disulfide bond between the cysteine in position 7 of the A-chain and the cysteine in position 7 of the B-chain, a disulfide bond between the cysteine in position 20 of the A-chain and the cysteine in position 19 of the B-chain and a disulfide bond between the cysteines in position 6 and 11 of the A-chain.

In the human body, the insulin hormone is synthesized as a single-chain precursor proinsulin (preproinsulin) consisting of a prepeptide of 24 amino acids followed by proinsulin containing 86 amino acids in the configuration: prepeptide-B-Arg Arg-C-Lys Arg-A, in which 10 C is a connecting peptide of 31 amino acids. Arg-Arg and Lys-Arg are cleavage sites for cleavage of the connecting peptide from the A and B chains.

In one aspect of the invention an insulin analogue which has two or more cysteine substitutions is provided, where the three disulfide bonds of human insulin are retained, and 15 wherein at least one amino acid residue in a position selected from the group consisting of A9, A10 and A12 of the A-chain is substituted with a cysteine, at least one amino acid residue in a position selected from the group consisting of B1, B2, B3, B4, B5 and B6 of the B-chain is substituted with a cysteine, at least one amino acid residue is substituted with an amino acid which is not a cysteine and optionally the amino acid in position B30 is deleted. In 20 one aspect of the invention the amino acid residue in position A10 of the A-chain is substituted with a cysteine, at least one amino acid residue in a position selected from the group consisting of B1, B2, B3, and B4 of the B-chain is substituted with a cysteine, at least one amino acid residue is substituted with an amino acid which is not a cysteine and optionally the amino acid in position B30 is deleted. In one aspect of the invention at least one amino 25 acid residue in a position selected from the group consisting of A9, A10 and A12 of the A-chain is substituted with a cysteine, at least one amino acid residue in a position selected from the group consisting of B1, B2, B3, B4, B5 and B6 of the B-chain is substituted with a cysteine, at least one amino acid residue in a position selected from the group consisting of A14, A21, B1, B3, B10, B16, B22, B25, B26, B27, B28, B29, B30, B31, B32 is substituted 30 with an amino acid which is not a cysteine and optionally the amino acid in position B30 is deleted. It is understood that when B1 or B3 is cysteine, the same amino acid can not be an amino acid which is not cysteine, whereas if e.g. B1 is cysteine B3 may according to the aspect of the invention be substituted with an amino acid which is not a cysteine and vice versa. In one aspect of the invention, the amino acid residue in position A10 of the A-chain is 35 substituted with a cysteine, at least one amino acid residue in a position selected from the

group consisting of B1, B2, B3, and B4 of the B-chain is substituted with a cysteine, at least one amino acid residue is substituted with an amino acid which is not a cysteine and optionally the amino acid in position B30 is deleted. In one aspect of the invention, the amino acid residue in position A10 of the A-chain is substituted with a cysteine, at least one amino acid residue in a position selected from the group consisting of B3 and B4 of the B-chain is substituted with a cysteine, at least one amino acid residue is substituted with an amino acid which is not a cysteine and optionally the amino acid in position B30 is deleted. In one aspect of the invention, the amino acid residue in position A10 of the A-chain is substituted with a cysteine, the amino acid residue in position B3 of the B-chain is substituted with a cysteine, at least one amino acid residue is substituted with an amino acid which is not a cysteine and optionally the amino acid in position B30 is deleted. In one aspect of the invention, the amino acid residue in position A10 of the A-chain is substituted with a cysteine, the amino acid residue in B4 of the B-chain is substituted with a cysteine, at least one amino acid residue is substituted with an amino acid which is not a cysteine and optionally the amino acid in position B30 is deleted. In one aspect of the invention, at least one amino acid residue which is substituted with an amino acid which is not a cysteine is in a position selected from the group consisting of A14, A21, B10, B16, B22, B25, B26, B27, B28, B29, B30, B31, B32.

In one aspect, insulin analogues according to the invention are obtained, wherein the amino acid in position B30 is deleted.

An additional disulfide bond obtained by the invention may be connecting two cysteines of the same chain, i.e. two cysteines in the A-chain or two cysteines in the B-chain of the insulin, or connecting a cysteine in the A-chain with a cysteine in the B-chain of the insulin. In one aspect, an insulin analogue according to the invention is obtained, wherein at least one additional disulfide bond is connecting two cysteines in the A-chain or connecting two cysteines in the B-chain. In one aspect, an insulin analogue according to the invention is obtained, wherein at least one additional disulfide bond is connecting a cysteine in the A-chain with a cysteine in the B-chain.

When used herein the term "additional disulfide bonds" means one or more disulfide bonds which are not present in human insulin.

In one aspect of the invention, cysteines are substituted into two positions of the insulin analogue, where the positions are selected from the group consisting of:

A10C, B1C;

A10C, B2C;

A10C, B3C;

A10C, B4C;

A10C, B5C; and

B1C, B4C.

In one aspect of the invention, cysteines are substituted into two positions of the insulin analogue, where the positions are selected from the group consisting of:

5 A10C, B1C;  
A10C, B2C;  
A10C, B3C;  
A10C, B4C; and  
B1C, B4C.

10 In one aspect of the invention, cysteines are substituted into two positions of the insulin analogue, where the positions are selected from the group consisting of:

A10C, B1C;  
A10C, B2C;  
A10C, B3C; and

15 A10C, B4C.

In one aspect of the invention, cysteines are substituted into two positions of the insulin analogue, where the positions are selected from the group consisting of:

A10C, B3C; and  
A10C, B4C.

20 In one aspect of the invention, cysteines are substituted into two positions of the insulin analogue, where the positions are A10C and B3C.

In one aspect of the invention, cysteines are substituted into two positions of the insulin analogue, where the positions are A10C and B4C.

25 In one aspect of the invention, an insulin analogue is obtained which comprises two cysteine substitutions resulting in one additional disulfide bond relative to human insulin.

“An insulin” according to the invention is herein to be understood as human insulin or desB30 human insulin

The term “insulin peptide” as used herein means a peptide which is either human insulin or an analogue or a derivative thereof with insulin activity.

30 The term “parent insulin” as used herein is intended to mean an insulin before any cysteine substitutions according to the invention have been applied thereto. In one aspect the parent insulin is selected from the group consisting of:

B28D human insulin,  
B28D, desB30 human insulin,  
35 A21G, B28E, desB30 human insulin,

A21G, B3Q, B28E, desB30 human insulin,  
A21G, desB1, B27E, B28K, desB29, desB30 human insulin,  
A21G, desB1, B3E, B27E, B28K, desB29, desB30 human insulin,  
A14E, B25H, desB30 human insulin,  
5 A14E, B16H, B25H, desB30 human insulin,  
A14E, B25H, desB27, desB30 human insulin,  
A14E, desB27, desB30 human insulin,  
A14H, B25H, desB30 human insulin, and  
A8H, A21G, B3E, B27E, desB30 human insulin.

10 In one aspect of the invention, the sites of cysteine substitutions are chosen in such a way that the human insulin analogue retains the desired biological activities associated with human insulin. Desired biological activities are known to the person skilled in the art and e.g. include binding to the insulin receptor, binding to the IGF-1 (Insulin Growth Factor 1) receptor, in vitro potency (measure of lipogenesis, glycogen synthesis), in vivo potency (steady state clamp, PK and PD experiments) as e.g. described in the Examples.

15 In one aspect, insulin analogues according to the invention are obtained, wherein the receptor binding to the insulin receptor is at least 1% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is at least 3% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is at least 5% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is at least 10% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is at least 15% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is at least 20% of the receptor binding of parent insulin to the insulin receptor.

20 In one aspect, insulin analogues according to the invention are obtained, wherein the receptor binding to the insulin receptor is increased. In one aspect, insulin analogues according to the invention are obtained, wherein the receptor binding to the insulin receptor is at least 110% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is at least 120% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is at least 130% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is at least 140% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is at least 150% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the

receptor binding to the insulin receptor is at least 160% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is between 110 and 200% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is between 120 and 180% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is between 140 and 180% of the receptor binding of parent insulin to the insulin receptor. In one aspect, the receptor binding to the insulin receptor is between 150 and 170% of the receptor binding of parent insulin to the insulin receptor.

5 The receptor binding to the insulin receptor may e.g. be determined as described  
10 below:

Insulin Receptor Binding Assay (on solubilised insulin receptor):

The affinity of the insulin analogue of the invention for the human insulin receptor is determined by a Scintillation Proximity Assay (SPA) (according to Glendorf *et al.* (2008), *Biochemistry*, 47, 4743-4751). Competition binding experiments were performed in 96-well plates (polystyrene Optiplate-96, PerkinElmer) on an Eppendorf epMotion 5075 robot using solubilized human IR (holoreceptor) semipurified by wheat germ agglutinin purification from baby hamster kidney (BHK) cells, which were stably transfected with the pZem vector containing the human IR-A or IR-B insert. Assays were initiated by making dilution series (eight dilutions, 5-fold each, first dilution 43-fold) of yeast supernatant containing the insulin analogue and a human insulin standard. A reagent mix consisting of SPA beads (SPA PVT Antibody-Binding Beads, Anti-Mouse Reagent Cat. No. RPNQ0017, GE Healthcare) resuspended in binding buffer, anti-IR monoclonal mouse antibody (83-7), solubilized human IR (hIR-A or hIR-B), and [<sup>125</sup>I]A14Tyr-labelled insulin was added to the dilution series of the appropriate samples. The final concentration of [<sup>125</sup>I]A14Tyr-labelled insulin was 7.5 pM, and the buffer consisted of 100 mM HEPES (pH 7.8), 100 mM NaCl, 10 mM MgSO<sub>4</sub>, and 0.025% (v/v) Tween 20. Plates were incubated with gentle shaking for 24 h at room temperature, centrifuged for 2 minutes at 2000 rpm, and counted in a TopCount NXT for 3 min/well. Data from the SPA were analyzed according to the four-parameter logistic model (Vølund, A., (1978), *Biometrics*, 34, 357-365.) and the affinities of the insulin analogue expressed relative 20 to that of human insulin.

30 Preparation of monoclonal mIR antibodies

Specific antibodies (F12 or 83-7) are produced by monoclonal technique: RBF mice are immunized by injecting 50 µg of purified mIR in FCA subcutaneously followed by two injections with 20 µg of mIR in FIA. High responder mice are boosted intravenously with 25 µg 35 of mIR and the spleens are harvested after 3 days. Spleen cells are fused with the myeloma

Fox cell line (Köhler, G & Milstein C. (1976), European J. Immunology, 6:511-19; Taggart RT et al (1983), Science 219:1228-30). Supernatants are screened for antibody production in a mIR specific ELISA. Positive wells are cloned and tested in Western blotting.

Insulin Receptor Binding Assay (on membrane-associated insulin receptor):

5 Binding of [<sup>125</sup>I]-human insulin to membrane-associated recombinant human insulin receptor isoform A (hIR-A).

Extraction of membrane-associated insulin receptors: BHK cells (tk- ts13) expressing the human insulin receptor isoform A from a ten-layer cell factory were harvested and homogenised in 25 ml of ice-cold buffer (25 mM HEPES pH 7.4, 2.5 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>,

10 250 mg/l bacitracin, 0.1 mM Pefablock (Roche)). The homogenate was layered carefully on 41% sucrose cushions, centrifuged in the ultracentrifuge at 95,000 x g for 75 minutes in a Beckman SW28 rotor at 4°C. The plasma membranes were collected from the top of the sucrose cushion, diluted 1:4 with buffer and centrifuged at 40,000 x g for 45min in a Beckman SW28 rotor. The pellets were suspended in buffer (25 mM HEPES pH 7.4, 2.5 mM CaCl<sub>2</sub>, 1

15 mM MgCl<sub>2</sub>, 250 mg/l bacitracin, 0.1 mM Pefablock) and stored at -80°C.

20 Radioligand binding to membrane-associated insulin receptors was performed in duplicate in 96-well OptiPlates (Perkin Elmer). Membrane protein was incubated for 150 minutes at 25°C with 50 pM [<sup>125</sup>I-Tyr<sup>A14</sup>]-human insulin in a total volume of 200 ml assay buffer (50 mM HEPES, 150 mM NaCl, 5 mM MgSO<sub>4</sub>, 0.01% Triton X-100, 0.1% HSA (fatty acid free), Complete™ EDTA-free protease inhibitors), increasing concentrations of human insulin or insulin analogue (typically between 0.01 and 300 nM), and 1 mg of WGA-coated PVT microspheres (GE Healthcare). The assay was terminated by centrifugation of the plate at 2000 RPM for 2 minutes, and bound radioactivity quantified by counting in a Packard TopCount NXT after a delay of 60 minutes.

25 The binding data were fitted using the four-parameter sigmoidal regression algorithm in GraphPad Prism 5.02 (GraphPad Software, San Diego, CA). Results are given as IC<sub>50</sub> relative to human insulin in %.

30 In one aspect an insulin analogue according to the invention is a modified insulin wherein two amino acid residues have been substituted by cysteine residues, one or more amino acid residues have been substituted by amino acid residues which are not cysteine residues and optionally the amino acid in position B30 has been deleted relative to the amino acid sequence of human insulin.

35 In one embodiment the amino acid residues which are not cysteine residues are selected from the group consisting of Ala, Arg, Asn, Asp, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr and Val. In one embodiment the amino acid residues which are

not cysteine residues are selected from the group consisting of Ala, Arg, Asn, Asp, Glu, Gln, Gly, His, Leu, Lys, Pro, Thr and Val. In one embodiment the amino acid residues which are not cysteine residues are selected from the group consisting of: A8H, A14E, A14H, A18L, A21G, A22K, desB1, B1G, B3Q, B3E, B3T, B3V, B3K, B3L, B16H, B16E, B22E, B24G, 5 B25A, B25H, B25N, B26G, B27G, B27E, B27D, B27P, desB27, B28G, B28D, B28E, B28K and B29R.

In one embodiment the amino acid residues which are not cysteine residues are selected from the group consisting of: A8H, A14E, A21G, A22K, desB1, B1G, B3Q, B3E, B10E, B16H, B16E, B24G, B25H, B25A, B25N, B25G, B26G, B27G, desB27, B27E, B28E, 10 B28D, B28G and B29R.

In one embodiment the amino acid residues which are not cysteine residues are selected from the group consisting of: A21G, desB1, B1G, B3Q, B3S, B3T and B3E.

In one embodiment the amino acid residues which are not cysteine residues are selected from the group consisting of: A8H, A14E, A14H, B16H, B10E, B16E, B25H, B25A, 15 B25N, B26G, B27G, B27E, B27P, desB27, B28G and B28E.

In one embodiment the amino acid residues which are not cysteine residues are selected from the group consisting of: A22K, B28E, B28D, desB27, A14E and B29R.

In one embodiment the amino acid residues which are not cysteine residues are selected from the group consisting of: B3K, B29E, B27E, B27D, desB27, B28E, B28D, B28K 20 and B29P

In one embodiment insulin analogues according to the invention also comprise one or more deletions. In one embodiment deletions are selected from the group consisting of: desB1, desB24, desB25 and/or desB27.

In one embodiment an insulin analogue according to the invention is a modified insulin wherein two amino acid residues have been substituted by cysteine residues, one or more amino acid residues have been substituted by amino acid residues selected from the group consisting of: Ala, Arg, Asn, Asp, Glu, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr and Val, and optionally the amino acid in position B30 has been deleted relative to the amino acid sequence of human insulin. In one embodiment an insulin analogue according to the invention is a modified insulin wherein two amino acid residues have been substituted by cysteine residues, one or more amino acid residues have been substituted by amino acid residues selected from the group consisting of: of Ala, Arg, Asn, Asp, Glu, Gln, Gly, His, Leu, Lys, Pro, Thr and Val, and optionally the amino acid in position B30 has been deleted relative to the amino acid sequence of human insulin. In one embodiment an insulin 30 analogue according to the invention is a modified insulin wherein two amino acid residues have been substituted by cysteine residues, one or more amino acid residues have been substituted by amino acid residues selected from the group consisting of: of Ala, Arg, Asn, Asp, Glu, Gln, Gly, His, Leu, Lys, Pro, Thr and Val, and optionally the amino acid in position B30 has been deleted relative to the amino acid sequence of human insulin. In one embodiment an insulin 35 analogue according to the invention is a modified insulin wherein two amino acid residues

have been substituted by cysteine residues, one or more amino acid residues have been substituted by amino acid residues selected from the group consisting of: A8H, A14E, A14H, A18L, A21G, A22K, desB1, B1G, B3Q, B3E, B3T, B3V, B3K, B3L, B16H, B16E, B22E, B24G, B25A, B25H, B25N, B26G, B26K, B27G, B27E, B27D, B27P, B27K, desB27, B28G, 5 B28D, B28E, B28K and B29R, and optionally the amino acid in position B30 has been deleted relative to the amino acid sequence of human insulin.

In one embodiment an insulin analogue according to the invention is a modified insulin wherein two amino acid residues have been substituted by cysteine residues, one or more amino acid residues have been substituted by amino acid residues selected from the 10 group consisting of: A8H, A14E, A21G, A22K, desB1, B1G, B3Q, B3E, B10E, B16H, B16E, B24G, B25H, B25A, B25N, B25G, B26G, B27G, desB27, B27E, B28E, B28D, B28G and B29R, and optionally the amino acid in position B30 has been deleted relative to the amino acid sequence of human insulin.

In one embodiment an insulin analogue according to the invention is a modified insulin 15 wherein two amino acid residues have been substituted by cysteine residues, one or more amino acid residues have been substituted by amino acid residues selected from the group consisting of: A21G, desB1, B1G, B3Q, B3S, B3T and B3E, and optionally the amino acid in position B30 has been deleted relative to the amino acid sequence of human insulin.

In one embodiment an insulin analogue according to the invention is a modified insulin 20 wherein two amino acid residues have been substituted by cysteine residues, one or more amino acid residues have been substituted by amino acid residues selected from the group consisting of: A8H, A14E, A14H, B16H, B10E, B16E, B25H, B25A, B25N, B26G, B27G, B27E, B27P, desB27, B28G and B28E, and optionally the amino acid in position B30 has been deleted relative to the amino acid sequence of human insulin.

25 In one an insulin analogue according to the invention is a modified insulin wherein two amino acid residues have been substituted by cysteine residues, one or more amino acid residues have been substituted by amino acid residues selected from the group consisting of: A22K, B28E, B28D, desB27, A14E and B29R, and optionally the amino acid in position B30 has been deleted relative to the amino acid sequence of human insulin.

30 In one embodiment an insulin analogue according to the invention is a modified insulin wherein two amino acid residues have been substituted by cysteine residues, one or more amino acid residues have been substituted by amino acid residues selected from the group consisting of: B3K, B29E, B27E, B27D, desB27, B28E, B28D, B28K and B29P, and 35 optionally the amino acid in position B30 has been deleted relative to the amino acid sequence of human insulin.

In one embodiment insulin analogues according to the invention also comprise one or more deletions. In one embodiment deletions are selected from the group consisting of: desB1, desB24, desB25 and/or desB27.

Examples of insulin analogues according to the invention are e.g.:

- 5           A10C, A14E, B4C, B25H, desB27, desB30 human insulin  
          A10C, A14E, B3C, B25H, desB27, desB30 human insulin  
          A10C, A14E, B2C, B25H, desB27, desB30 human insulin  
          A10C, A14E, B1C, B25H, desB27, desB30 human insulin  
          A10C, A14E, B4C, desB27, desB30 human insulin  
10           A10C, A14E, B3C, desB27, desB30 human insulin  
          A10C, A14E, B2C, desB27, desB30 human insulin  
          A10C, A14E, B1C, desB27, desB30 human insulin  
          A10C, B4C, B25H, desB30 human insulin  
          A10C, B3C, B25H, desB30 human insulin  
15           A10C, B2C, B25H, desB30 human insulin  
          A10C, B1C, B25H, desB30 human insulin  
          A10C, A14E, B4C, B25H, desB30 human insulin  
          A10C, A14E, B3C, B25H, desB30 human insulin  
          A10C, A14E, B2C, B25H, desB30 human insulin  
20           A10C, A14E, B1C, B25H, desB30 human insulin  
          A10C, A14E, B4C, desB30 human insulin  
          A10C, A14E, B3C, desB30 human insulin  
          A10C, A14E, B2C, desB30 human insulin  
          A10C, A14E, B1C, desB30 human insulin  
25           A10C, A14E, desB1, B4C, B25H, desB30 human insulin  
          A10C, A14E, desB1, B3C, B25H, desB30 human insulin  
          A10C, A14E, desB1, B2C, B25H, desB30 human insulin  
          A10C, A14E, desB1, B1C, B25H, desB30 human insulin  
          A10C, A14E, B4C, B25H, B28E, desB30 human insulin  
30           A10C, A14E, B3C, B25H, B28E, desB30 human insulin  
          A10C, A14E, B2C, B25H, B28E, desB30 human insulin  
          A10C, A14E, B1C, B25H, B28E, desB30 human insulin  
          A10C, A14H, B4C, B25H, desB30 human insulin  
          A10C, A14H, B3C, B25H, desB30 human insulin  
35           A10C, A14H, B2C, B25H, desB30 human insulin

A10C, A14H, B1C, B25H, desB30 human insulin  
A10C, A14E, B4C, B16H, B25H, desB30 human insulin  
A10C, A14E, B3C, B16H, B25H, desB30 human insulin  
A10C, A14E, B2C, B16H, B25H, desB30 human insulin  
5 A10C, A14E, B1C, B16H, B25H, desB30 human insulin  
A8H, A21C and B25C human insulin,  
A21C, B10E and B25C human insulin,  
A8H, A21C, B10E and B25C human insulin,  
A10C, A14E, B4C, B25A, desB30 human insulin  
10 A10C, A14E, B3C, B25A, desB30 human insulin  
A10C, A14E, B2C, B25A, desB30 human insulin  
A10C, A14E, B1C, B25A, desB30 human insulin  
A10C, A14E, B4C, B25N, B27E, desB30 human insulin  
A10C, A14E, B3C, B25N, B27E, desB30 human insulin  
15 A10C, A14E, B2C, B25N, B27E, desB30 human insulin  
A10C, A14E, B1C, B25N, B27E, desB30 human insulin  
A10C, A14E, B4C, B25N, desB27, desB30 human insulin  
A10C, A14E, B3C, B25N, desB27, desB30 human insulin  
A10C, A14E, B2C, B25N, desB27, desB30 human insulin  
20 A10C, A14E, B1C, B25N, desB27, desB30 human insulin  
A10C, A21G, B3C, B28E, desB30 human insulin  
A10C, A21G, B4C, B28E, desB30 human insulin  
A10C, A21G, B3Q, B4C, B28E, desB30 human insulin  
A10C, B2C, B3E, desB30 human insulin  
25 A10C, B3T, B4C, desB30 human insulin  
A10C, B3V, B4C, desB30 human insulin  
A10C, A21G, B3E, B4C, B28E, desB30 human insulin  
A10C, A21G, B3E, B4C, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, B3K, B4C, B28E, desB30 human insulin  
30 A10C, A21G, desB1, B2C, B3E, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, desB1, B3E, B4C, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, desB1, B3C, B27E, B28K, desB29, desB30 human insulin  
A10C, B3Q, B4C, desB30 human insulin  
A10C, A21G, B3E, B4C, B22E, B28E, desB30 human insulin  
35 A10C, A21G, B3E, B4C, desB24, B28E, desB30 human insulin

A10C, B3C, B28D, desB30 human insulin  
A10C, B2C, B28D, desB30 human insulin  
A10C, B1C, B28D, desB30 human insulin  
A10C, B4C, B28D, desB30 human insulin  
5 A10C, B1C, B28E, desB30 human insulin  
A10C, B2C, B28E, desB30 human insulin  
A10C, B3C, B28E, desB30 human insulin  
A10C, B4C, B28E, desB30 human insulin  
A10C, A21G, desB1, B3Q, B4C, B28E, desB30 human insulin  
10 A10C, A21G, desB1, B3E, B4C, B28E, desB30 human insulin  
A10C, A21G, B2C, B3E, B28E, desB30 human insulin  
A10C, A21G, desB1, B2C, B3E, B28E, desB30 human insulin  
A10C, A21G, desB1, B3C, B28E, desB30 human insulin  
A10C, A21G, B2C, B3E, B27E, B28K, desB29, desB30 human insulin  
15 A10C, A21G, B3C, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, desB1, B3C, B27E, desB30 human insulin  
A10C, A21G, B1G, B3C, B27E, desB30 human insulin  
A10C, A21G, B1G, B3E, B4C, B27E, desB30 human insulin  
A10C, A21G, desB1, B3E, B4C, B27E, desB30 human insulin  
20 A8H, A10C, A21G, desB1, B3E, B4C, B27E, desB30 human insulin  
A8H, A10C, A21G, desB1, B3C, B27E, desB30 human insulin  
A10C, A14E, A21G, B1G, B3C, B27E, desB30 human insulin  
A10C, A14E, A21G, B1G, B3E, B4C, B27E, desB30 human insulin  
A10C, A21G, B1G, B3C, B27E, B28E, desB30 human insulin  
25 A10C, A21G, B0G, B1E, B3C, B27E, B28E, desB30 human insulin  
A10C, A14E, A21G, B1G, B3C, B27E, B28E, desB30 human insulin  
A10C, A14E, A21G, B0G, B1E, B3C, B27E, B28E, desB30 human insulin  
A10C, A21G, B1G, B3C, B27P, B28E, desB30 human insulin  
A10C, A21G, B0G, B1E, B3C, B27P, B28E, desB30 human insulin  
30 A10C, A14E, A21G, B1G, B3C, B27P, B28E, desB30 human insulin  
A10C, A14E, A21G, B0G, B1E, B3C, B27P, B28E, desB30 human insulin  
A10C, A21G, B3E, B4C, desB25, B28E, desB30 human insulin  
A10C, B3E, B4C, desB30 human insulin  
A10C, B3L, B4C, desB30 human insulin  
35 A10C, A22K, B1C, B29R, desB30 human insulin

- A10C, A22K, B2C, B29R, desB30 human insulin  
A10C, A22K, B3C, B29R, desB30 human insulin  
A10C, A22K, B4C, B29R, desB30 human insulin  
A10C, A22K, B4C, desB27, B29R, desB30 human insulin  
5 A10C, A22K, B3C, desB27, B29R, desB30 human insulin  
A10C, A22K, B2C, desB27, B29R, desB30 human insulin  
A10C, A22K, B1C, desB27, B29R, desB30 human insulin  
A10C, A14E, A22K, B1C, B29R, desB30 human insulin  
A10C, A14E, A22K, B2C, B29R, desB30 human insulin  
10 A10C, A14E, A22K, B3C, B29R, desB30 human insulin  
A10C, A14E, A22K, B4C, B29R, desB30 human insulin  
A10C, A14E, A22K, B4C, desB27, B29R, desB30 human insulin  
A10C, A14E, A22K, B3C, desB27, B29R, desB30 human insulin  
A10C, A14E, A22K, B2C, desB27, B29R, desB30 human insulin  
15 A10C, A14E, A22K, B1C, desB27, B29R, desB30 human insulin  
A10C, A14E, A22K, B4C, B28E, B29R, desB30 human insulin  
A10C, A14E, A22K, B3C, B28E, B29R, desB30 human insulin  
A10C, A14E, A22K, B2C, B28E, B29R, desB30 human insulin  
A10C, A14E, A22K, B1C, B28E, B29R, desB30 human insulin  
20 A10C, A14E, A22K, B4C, B28D, B29R, desB30 human insulin  
A10C, A14E, A22K, B3C, B28D, B29R, desB30 human insulin  
A10C, A14E, A22K, B2C, B28D, B29R, desB30 human insulin  
A10C, A14E, A22K, B1C, B28D, B29R, desB30 human insulin  
A10C, A14E, B1C, B16H, B25H, desB30 human insulin  
25 A10C, A14E, B2C, B16H, B25H, desB30 human insulin  
A10C, A14E, B3C, B16H, B25H, desB30 human insulin  
A10C, A14E, B4C, B16H, B25H, desB30 human insulin  
A10C, A14E, B1C, B16E, B25H, desB30 human insulin  
A10C, A14E, B2C, B16E, B25H, desB30 human insulin  
30 A10C, A14E, B3C, B16E, B25H, desB30 human insulin  
A10C, A14E, B4C, B16E, B25H, desB30 human insulin  
In one embodiment an insulin analogue according to the invention comprises be-  
35 tween 3 and 9 substitutions relative to human insulin wherein two substitutions are to cys-  
teine residues and one or more substitutions are to amino acid residues which are not cys-  
teine residues, alternatively an insulin analogue according to the invention comprises be-

tween 3 and 8 substitutions relative to human insulin, alternatively between 3 and 7 substitutions relative to human insulin, alternatively between 3 and 6 substitutions relative to human insulin, alternatively between 3 and 5 substitutions relative to human insulin, alternatively between 3 and 4 substitutions relative to human insulin, or alternatively 3 substitutions relative to human insulin wherein two substitutions are to cysteine residues and one or more substitutions are to amino acid residues which are not cysteine residues.

5 Modifications in the insulin molecule are denoted stating the chain (A or B), the position, and the one or three letter code for the amino acid residue substituting the native amino acid residue.

10 Herein terms like "A1", "A2" and "A3" etc. indicates the amino acid in position 1, 2 and 3 etc., respectively, in the A chain of insulin (counted from the N-terminal end). Similarly, terms like B1, B2 and B3 etc. indicates the amino acid in position 1, 2 and 3 etc., respectively, in the B chain of insulin (counted from the N-terminal end). Using the one letter codes for amino acids, a term like A10C designates that the amino acid in the A10 position is cysteine. Using the three letter codes for amino acids, the corresponding expression is A10Cys.

15 By "desB30" or "B(1-29)" is meant a natural insulin B chain or an analogue thereof lacking the B30 amino acid and "A(1-21)" means the natural insulin A chain. Thus, e.g., A10C,B1C,desB30 human insulin or alternatively A10Cys,B1Cys,desB30 human insulin is an analogue of human insulin where the amino acid in position 10 in the A chain is substituted with cysteine, the amino acid in position 1 in the B chain is substituted with cysteine, and the amino acid in position 30 in the B chain is deleted.

20 Herein, the term "amino acid residue" is an amino acid from which a hydroxy group has been removed from a carboxy group and/or from which a hydrogen atom has been removed from an amino group.

25 In one embodiment, an insulin analogue according to the invention is selected from the group consisting of:

A10C, A14E, B4C, B25H, desB27, desB30 human insulin

A10C, A14E, B3C, B25H, desB27, desB30 human insulin

A10C, A14E, B2C, B25H, desB27, desB30 human insulin

30 A10C, A14E, B1C, B25H, desB27, desB30 human insulin

A10C, A14E, B4C, desB27, desB30 human insulin

A10C, A14E, B3C, desB27, desB30 human insulin

A10C, A14E, B2C, desB27, desB30 human insulin

A10C, A14E, B1C, desB27, desB30 human insulin

35 A10C, B4C, B25H, desB30 human insulin

A10C, B3C, B25H, desB30 human insulin  
A10C, B2C, B25H, desB30 human insulin  
A10C, B1C, B25H, desB30 human insulin  
A10C, A14E, B4C, B25H, desB30 human insulin  
5 A10C, A14E, B3C, B25H, desB30 human insulin  
A10C, A14E, B2C, B25H, desB30 human insulin  
A10C, A14E, B1C, B25H, desB30 human insulin  
A10C, A14E, B4C, desB30 human insulin  
A10C, A14E, B3C, desB30 human insulin  
10 A10C, A14E, B2C, desB30 human insulin  
A10C, A14E, B1C, desB30 human insulin  
A10C, A14E, desB1, B4C, B25H, desB30 human insulin  
A10C, A14E, desB1, B3C, B25H, desB30 human insulin  
A10C, A14E, desB1, B2C, B25H, desB30 human insulin  
15 A10C, A14E, desB1, B1C, B25H, desB30 human insulin  
A10C, A14E, B4C, B25H, B28E, desB30 human insulin  
A10C, A14E, B3C, B25H, B28E, desB30 human insulin  
A10C, A14E, B2C, B25H, B28E, desB30 human insulin  
A10C, A14E, B1C, B25H, B28E, desB30 human insulin  
20 A10C, A14H, B4C, B25H, desB30 human insulin  
A10C, A14H, B3C, B25H, desB30 human insulin  
A10C, A14H, B2C, B25H, desB30 human insulin  
A10C, A14H, B1C, B25H, desB30 human insulin  
A10C, A14E, B4C, B16H, B25H, desB30 human insulin  
25 A10C, A14E, B3C, B16H, B25H, desB30 human insulin  
A10C, A14E, B2C, B16H, B25H, desB30 human insulin  
A10C, A14E, B1C, B16H, B25H, desB30 human insulin  
A10C, A14E, B4C, B25A, desB30 human insulin  
A10C, A14E, B3C, B25A, desB30 human insulin  
30 A10C, A14E, B2C, B25A, desB30 human insulin  
A10C, A14E, B1C, B25A, desB30 human insulin  
A10C, A14E, B4C, B25N, B27E, desB30 human insulin  
A10C, A14E, B3C, B25N, B27E, desB30 human insulin  
A10C, A14E, B2C, B25N, B27E, desB30 human insulin  
35 A10C, A14E, B1C, B25N, B27E, desB30 human insulin

A10C, A14E, B4C, B25N, desB27, desB30 human insulin  
A10C, A14E, B3C, B25N, desB27, desB30 human insulin  
A10C, A14E, B2C, B25N, desB27, desB30 human insulin  
A10C, A14E, B1C, B25N, desB27, desB30 human insulin  
5 A10C, B1C, desB27, desB30 human insulin  
A10C, B2C, desB27, desB30 human insulin  
A10C, B3C, desB27, desB30 human insulin  
A10C, B4C, desB27, desB30 human insulin  
A10C, A14E, A22K, B4C, B25H, desB27, desB30 human insulin  
10 A10C, A14E, A22K, B3C, B25H, desB27, desB30 human insulin  
A10C, A14E, A22K, B2C, B25H, desB27, desB30 human insulin  
A10C, A14E, A22K, B1C, B25H, desB27, desB30 human insulin  
A10C, A14E, A22K, B4C, desB27, desB30 human insulin  
A10C, A14E, A22K, B3C, desB27, desB30 human insulin  
15 A10C, A14E, A22K, B2C, desB27, desB30 human insulin  
A10C, A14E, A22K, B1C, desB27, desB30 human insulin  
A10C, A22K, B4C, B25H, desB30 human insulin  
A10C, A22K, B3C, B25H, desB30 human insulin  
A10C, A22K, B2C, B25H, desB30 human insulin  
20 A10C, A22K, B1C, B25H, desB30 human insulin  
A10C, A14E, A22K, B4C, B25H, desB30 human insulin  
A10C, A14E, A22K, B3C, B25H, desB30 human insulin  
A10C, A14E, A22K, B2C, B25H, desB30 human insulin  
A10C, A14E, A22K, B1C, B25H, desB30 human insulin  
25 A10C, A14E, A22K, B4C, desB30 human insulin  
A10C, A14E, A22K, B3C, desB30 human insulin  
A10C, A14E, A22K, B2C, desB30 human insulin  
A10C, A14E, A22K, B1C, desB30 human insulin  
A10C, A14E, A22K, B4C, B25H, desB30 human insulin  
30 A10C, A14E, A22K, desB1, B3C, B25H, desB30 human insulin  
A10C, A14E, A22K, desB1, B2C, B25H, desB30 human insulin  
A10C, A14E, A22K, desB1, B1C, B25H, desB30 human insulin  
A10C, A14E, A22K, B4C, B25H, B28E, desB30 human insulin  
A10C, A14E, A22K, B3C, B25H, B28E, desB30 human insulin  
35 A10C, A14E, A22K, B2C, B25H, B28E, desB30 human insulin

- A10C, A14E, A22K, B1C, B25H, B28E, desB30 human insulin  
A10C, A14H, B4C, B25H, desB30 human insulin  
A10C, A14H, B3C, B25H, desB30 human insulin  
A10C, A14H, B2C, B25H, desB30 human insulin  
5 A10C, A14H, B1C, B25H, desB30 human insulin  
A10C, A14E, A22K, B4C, B16H, B25H, desB30 human insulin  
A10C, A14E, A22K, B3C, B16H, B25H, desB30 human insulin  
A10C, A14E, A22K, B2C, B16H, B25H, desB30 human insulin  
A10C, A14E, A22K, B1C, B16H, B25H, desB30 human insulin  
10 A10C, A14E, A22K, B4C, B25A, desB30 human insulin  
A10C, A14E, A22K, B3C, B25A, desB30 human insulin  
A10C, A14E, A22K, B2C, B25A, desB30 human insulin  
A10C, A14E, A22K, B1C, B25A, desB30 human insulin  
A10C, A14E, A22K, B4C, B25N, B27E, desB30 human insulin  
15 A10C, A14E, A22K, B3C, B25N, B27E, desB30 human insulin  
A10C, A14E, A22K, B2C, B25N, B27E, desB30 human insulin  
A10C, A14E, A22K, B1C, B25N, B27E, desB30 human insulin  
A10C, A14E, A22K, B4C, B25N, desB27, desB30 human insulin  
A10C, A14E, A22K, B3C, B25N, desB27, desB30 human insulin  
20 A10C, A14E, A22K, B2C, B25N, desB27, desB30 human insulin  
A10C, A14E, A22K, B1C, B25N, desB27, desB30 human insulin  
A10C, A22K, B1C, desB27, desB30 human insulin  
A10C, A22K, B2C, desB27, desB30 human insulin  
A10C, A22K, B3C, desB27, desB30 human insulin  
25 A10C, A22K, B4C, desB27, desB30 human insulin

In one embodiment, an insulin analogue according to the invention is selected from the group consisting of:

- A8H, A14E, A21C, B25H, B26C, desB30 human insulin  
30 A8H, A21C, B26C, desB30 human insulin,  
A21C, B10E, B26C, desB30 human insulin,  
A8H, A21C, B10E, B26C, desB30 human insulin,  
A8H, A21C, B25C, desB30 human insulin,  
A21C, B10E, B25C, desB30 human insulin,  
35 A8H, A21C, B10E, B25C, desB30 human insulin

In one embodiment, an insulin analogue according to the invention is selected from the group consisting of:

A8H, A14E, A21C, A22K, B25H, B26C, desB30 human insulin  
A8H, A21C, A22K, B26C, desB30 human insulin,  
5 A21C, A22K, B10E, B26C, desB30 human insulin,  
A8H, A21C, A22K, B10E, B26C, desB30 human insulin,  
A8H, A21C, A22K, B25C, desB30 human insulin,  
A21C, A22K, B10E, B25C, desB30 human insulin,  
A8H, A21C, A22K, B10E, B25C, desB30 human insulin  
10 A8H, A14E, A21C, A22K, B25H, B26C, B29R, desB30 human insulin  
A8H, A21C, A22K, B26C, B29R, desB30 human insulin,  
A21C, A22K, B10E, B26C, B29R, desB30 human insulin,  
A8H, A21C, A22K, B10E, B26C, B29R, desB30 human insulin,  
A8H, A21C, A22K, B25C, B29R, desB30 human insulin,  
15 A21C, A22K, B10E, B25C, B29R, desB30 human insulin,  
A8H, A21C, A22K, B10E, B25C, B29R, desB30 human insulin

In one embodiment, an insulin analogue according to the invention is selected from

20 the group consisting of:  
A10C, A21G, B3C, B28E, desB30 human insulin;  
A10C, A21G, B4C, B28E, desB30 human insulin;  
A10C, A21G, B3Q, B4C, B28E, desB30 human insulin;  
A10C, B2C, B3E, desB30 human insulin;  
25 A10C, B3T, B4C, desB30 human insulin;  
A10C, B3V, B4C, desB30 human insulin;  
A10C, A21G, B3E, B4C, B28E, desB30 human insulin;  
A10C, A21G, B3E, B4C, B27E, B28K, desB29, desB30 human insulin;  
A10C, A21G, B3K, B4C, B28E, desB30 human insulin;  
30 A10C, A21G, desB1, B2C, B3E, B27E, B28K, desB29, desB30 human insulin;  
A10C, A21G, desB1, B3E, B4C, B27E, B28K, desB29, desB30 human insulin;  
A10C, A21G, desB1, B3C, B27E, B28K, desB29, desB30 human insulin;  
A10C, B3Q, B4C, desB30 human insulin;  
A10C, A21G, B3E, B4C, B22E, B28E, desB30 human insulin;  
35 A10C, A21G, B3E, B4C, desB24, B28E, desB30 human insulin;

A10C, B3C, B28D, desB30 human insulin;  
A10C, B2C, B28D, desB30 human insulin;  
A10C, B1C, B28D, desB30 human insulin;  
A10C, B4C, B28D, desB30 human insulin;  
5 A10C, B1C, B28E, desB30 human insulin;  
A10C, B2C, B28E, desB30 human insulin;  
A10C, B3C, B28E, desB30 human insulin;  
A10C, B4C, B28E, desB30 human insulin;  
A10C, A21G, desB1, B3Q, B4C, B28E, desB30 human insulin;  
10 A10C, A21G, desB1, B3E, B4C, B28E, desB30 human insulin;  
A10C, A21G, B2C, B3E, B28E, desB30 human insulin;  
A10C, A21G, desB1, B2C, B3E, B28E, desB30 human insulin;  
A10C, A21G, desB1, B3C, B28E, desB30 human insulin;  
A10C, A21G, B2C, B3E, B27E, B28K, desB29, desB30 human insulin;  
15 A10C, A21G, B3C, B27E, B28K, desB29, desB30 human insulin;  
A10C, A21G, desB1, B3C, B27E, desB30 human insulin;  
A10C, A21G, B1G, B3C, B27E, desB30 human insulin;  
A10C, A21G, B1G, B3E, B4C, B27E, desB30 human insulin;  
A10C, A21G, desB1, B3E, B4C, B27E, desB30 human insulin;  
20 A8H, A10C, A21G, desB1, B3E, B4C, B27E, desB30 human insulin;  
A8H, A10C, A21G, desB1, B3C, B27E, desB30 human insulin;  
A10C, A14E, A21G, B1G, B3C, B27E, desB30 human insulin;  
A10C, A14E, A21G, B1G, B3E, B4C, B27E, desB30 human insulin;  
A10C, A21G, B1G, B3C, B27E, B28E, desB30 human insulin;  
25 A10C, A21G, B0G, B1E, B3C, B27E, B28E, desB30 human insulin;  
A10C, A14E, A21G, B1G, B3C, B27E, B28E, desB30 human insulin;  
A10C, A14E, A21G, B0G, B1E, B3C, B27E, B28E, desB30 human insulin;  
A10C, A21G, B1G, B3C, B27P, B28E, desB30 human insulin;  
A10C, A21G, B0G, B1E, B3C, B27P, B28E, desB30 human insulin;  
30 A10C, A14E, A21G, B1G, B3C, B27P, B28E, desB30 human insulin;  
A10C, A14E, A21G, B0G, B1E, B3C, B27P, B28E, desB30 human insulin;  
A10C, A21G, B3E, B4C, desB25, B28E, desB30 human insulin;  
A10C, B3E, B4C, desB30 human insulin;  
A10C, B3L, B4C, desB30 human insulin;  
35 A10C, B1C, desB27, desB30 human insulin;

A10C, B2C, desB27, desB30 human insulin;  
A10C, B3C, desB27, desB30 human insulin;  
A10C, B4C, desB27, desB30 human insulin;  
A10C, B4C and B29E human insulin;  
5 A10C, B4C, B28K and B29P human insulin;  
A10C, B3C and B28D human insulin;  
A10C, B3C and B29E human insulin;  
A10C, B3C, B28K and B29P human insulin; or  
A10C, B3K, B4C and B29E human insulin.

10

In one embodiment, an insulin analogue according to the invention is selected from the group consisting of:

A10C, A22K, B1C, B29R, desB30 human insulin  
A10C, A22K, B2C, B29R, desB30 human insulin  
15 A10C, A22K, B3C, B29R, desB30 human insulin  
A10C, A22K, B4C, B29R, desB30 human insulin  
A10C, A22K, B4C, desB27, B29R, desB30 human insulin  
A10C, A22K, B3C, desB27, B29R, desB30 human insulin  
A10C, A22K, B2C, desB27, B29R, desB30 human insulin  
20 A10C, A22K, B1C, desB27, B29R, desB30 human insulin  
A10C, A14E, A22K, B1C, B29R, desB30 human insulin  
A10C, A14E, A22K, B2C, B29R, desB30 human insulin  
A10C, A14E, A22K, B3C, B29R, desB30 human insulin  
A10C, A14E, A22K, B4C, B29R, desB30 human insulin  
25 A10C, A14E, A22K, B4C, desB27, B29R, desB30 human insulin  
A10C, A14E, A22K, B3C, desB27, B29R, desB30 human insulin  
A10C, A14E, A22K, B2C, desB27, B29R, desB30 human insulin  
A10C, A14E, A22K, B1C, desB27, B29R, desB30 human insulin  
A10C, A14E, A22K, B4C, B28E, B29R, desB30 human insulin  
30 A10C, A14E, A22K, B3C, B28E, B29R, desB30 human insulin  
A10C, A14E, A22K, B2C, B28E, B29R, desB30 human insulin  
A10C, A14E, A22K, B1C, B28E, B29R, desB30 human insulin  
A10C, A14E, A22K, B4C, B28D, B29R, desB30 human insulin  
A10C, A14E, A22K, B3C, B28D, B29R, desB30 human insulin  
35 A10C, A14E, A22K, B2C, B28D, B29R, desB30 human insulin

A10C, A14E, A22K, B1C, B28D, B29R, desB30 human insulin

In one embodiment, an insulin analogue according to the invention is selected from the group consisting of:

- 5 A10C, A22K, B1C, desB30 human insulin
- A10C, A22K, B2C, desB30 human insulin
- A10C, A22K, B3C, desB30 human insulin
- A10C, A22K, B4C, desB30 human insulin
- A10C, A22K, B4C, desB27, desB30 human insulin
- 10 A10C, A22K, B3C, desB27, desB30 human insulin
- A10C, A22K, B2C, desB27, desB30 human insulin
- A10C, A22K, B1C, desB27, desB30 human insulin
- A10C, A14E, A22K, B1C, desB30 human insulin
- A10C, A14E, A22K, B2C, desB30 human insulin
- 15 A10C, A14E, A22K, B3C, desB30 human insulin
- A10C, A14E, A22K, B4C, desB30 human insulin
- A10C, A14E, A22K, B4C, desB27, desB30 human insulin
- A10C, A14E, A22K, B3C, desB27, desB30 human insulin
- A10C, A14E, A22K, B2C, desB27, desB30 human insulin
- 20 A10C, A14E, A22K, B1C, desB27, desB30 human insulin
- A10C, A22K, B4C, B28E, desB30 human insulin
- A10C, A22K, B3C, B28E, desB30 human insulin
- A10C, A22K, B2C, B28E, desB30 human insulin
- A10C, A22K, B1C, B28E, desB30 human insulin
- 25 A10C, A22K, B4C, B28D, desB30 human insulin
- A10C, A22K, B3C, B28D, desB30 human insulin
- A10C, A22K, B2C, B28D, desB30 human insulin
- A10C, A22K, B1C, B28D, desB30 human insulin
- A10C, A14E, A22K, B4C, B28E, desB30 human insulin
- 30 A10C, A14E, A22K, B3C, B28E, desB30 human insulin
- A10C, A14E, A22K, B2C, B28E, desB30 human insulin
- A10C, A14E, A22K, B1C, B28E, desB30 human insulin
- A10C, A14E, A22K, B4C, B28D, desB30 human insulin
- A10C, A14E, A22K, B3C, B28D, desB30 human insulin
- 35 A10C, A14E, A22K, B2C, B28D, desB30 human insulin

A10C, A14E, A22K, B1C, B28D, desB30 human insulin

In one embodiment, an insulin analogue according to the invention is selected from the group consisting of:

- 5 A10C, A14E, B1C, B16H, B25H, desB30 human insulin
- A10C, A14E, B2C, B16H, B25H, desB30 human insulin
- A10C, A14E, B3C, B16H, B25H, desB30 human insulin
- A10C, A14E, B4C, B16H, B25H, desB30 human insulin
- A10C, A14E, B1C, B16E, B25H, desB30 human insulin
- 10 A10C, A14E, B2C, B16E, B25H, desB30 human insulin
- A10C, A14E, B3C, B16E, B25H, desB30 human insulin
- A10C, A14E, B4C, B16E, B25H, desB30 human insulin
- A10C, A14E, A22K, B1C, B16H, B25H, B29R, desB30 human insulin
- A10C, A14E, A22K, B2C, B16H, B25H, B29R, desB30 human insulin
- 15 A10C, A14E, A22K, B3C, B16H, B25H, B29R, desB30 human insulin
- A10C, A14E, A22K, B4C, B16H, B25H, B29R, desB30 human insulin
- A10C, A14E, A22K, B1C, B16E, B25H, B29R, desB30 human insulin
- A10C, A14E, A22K, B2C, B16E, B25H, B29R, desB30 human insulin
- A10C, A14E, A22K, B3C, B16E, B25H, B29R, desB30 human insulin
- 20 A10C, A14E, A22K, B4C, B16E, B25H, B29R, desB30 human insulin

In one embodiment, an insulin analogue according to the invention is selected from the group consisting of:

- 25 A10C, A14E, A22K, B1C, B16H, B25H, desB30 human insulin
- A10C, A14E, A22K, B2C, B16H, B25H, desB30 human insulin
- A10C, A14E, A22K, B3C, B16H, B25H, desB30 human insulin
- A10C, A14E, A22K, B4C, B16H, B25H, desB30 human insulin
- A10C, A14E, A22K, B1C, B16E, B25H, desB30 human insulin
- A10C, A14E, A22K, B2C, B16E, B25H, desB30 human insulin
- 30 A10C, A14E, A22K, B3C, B16E, B25H, desB30 human insulin
- A10C, A14E, A22K, B4C, B16E, B25H, desB30 human insulin

In one embodiment, an insulin analogue according to the invention is selected from the group consisting of:

- 35 A10C, A21G, B3C, B28E, desB30 human insulin

A10C, A21G, B4C, B28E, desB30 human insulin  
A10C, A21G, B3Q, B4C, B28E, desB30 human insulin  
A10C, B2C, B3E, desB30 human insulin  
A10C, B3T, B4C, desB30 human insulin  
5 A10C, B3V, B4C, desB30 human insulin  
A10C, A21G, B3E, B4C, B28E, desB30 human insulin  
A10C, A21G, B3E, B4C, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, B3K, B4C, B28E, desB30 human insulin  
A10C, A21G, desB1, B2C, B3E, B27E, B28K, desB29, desB30 human insulin  
10 A10C, A21G, desB1, B3E, B4C, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, desB1, B3C, B27E, B28K, desB29, desB30 human insulin  
A10C, A22K, B3C, desB27, desB30 human insulin  
A10C, A14E, B4C, B25H, desB30 human insulin  
A10C, A14E, B4C, B25H, desB27, desB30 human insulin  
15 A10C, B4C, B28D, desB30 human insulin  
A10C, B4C, B25H, desB30 human insulin  
A10C, A14E, B3C, B25H, desB30 human insulin  
A10C, B3C, B25H, desB30 human insulin  
A10C, A14E, B3C, B25H, desB27, desB30 human insulin  
20 A10C, A14E, desB1, B4C, B25H, desB30 human insulin  
A10C, A14E, B4C, B25H, B28E, desB30 human insulin  
A10C, A14H, B4C, B25H, desB30 human insulin  
A10C, A14E, B2C, B25H, desB30 human insulin  
A10C, A14E, B1C, B25H, desB30 human insulin  
25 A10C, A14E, B3C, B16H, B25H, desB30 human insulin  
A10C, B4C, B28D human insulin  
A10C, A14E, B3C, desB27, desB30 human insulin  
A10C, B3Q, B4C, desB30 human insulin  
A10C, A21G, B3E, B4C, B22E, B28E, desB30 human insulin  
30 A10C, A21G, B3E, B4C, desB24, B28E, desB30 human insulin  
A10C, B2C, B28D, desB30 human insulin  
A10C, B1C, B28D, desB30 human insulin  
A10C, A21G, desB1, B3Q, B4C, B28E, desB30 human insulin  
A10C, A21G, desB1, B3E, B4C, B28E, desB30 human insulin  
35 A10C, A21G, B2C, B3E, B28E, desB30 human insulin

A10C, A21G, desB1, B2C, B3E, B28E, desB30 human insulin  
A10C, A21G, desB1, B3C, B28E, desB30 human insulin  
A10C, A21G, B2C, B3E, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, B3C, B27E, B28K, desB29, desB30 human insulin  
5 A10C, A21G, desB1, B3C, B27E, desB30 human insulin  
A10C, A21G, B1G, B3C, B27E, desB30 human insulin  
A10C, A21G, B1G, B3E, B4C, B27E, desB30 human insulin  
A10C, B2C, B3A, desB30 human insulin  
A10C, B2C, B3R, desB30 human insulin  
10 A10C, B2C, B3D, desB30 human insulin  
A10C, B2C, B3Q, desB30 human insulin  
A10C, B2C, B3G, desB30 human insulin  
A10C, B2C, B3H, desB30 human insulin  
A10C, B2C, B3I, desB30 human insulin  
15 A10C, B2C, B3L, desB30 human insulin  
A10C, B2C, B3K, desB30 human insulin  
A10C, B2C, B3M, desB30 human insulin  
A10C, B2C, B3F, desB30 human insulin  
A10C, B2C, B3P, desB30 human insulin  
20 A10C, B2C, B3S, desB30 human insulin  
A10C, B2C, B3T, desB30 human insulin  
A10C, B2C, B3W, desB30 human insulin  
A10C, B2C, B3Y, desB30 human insulin  
A10C, B2C, B3V, desB30 human insulin  
25 A10C, B3R, B4C, desB30 human insulin  
A10C, B3D, B4C, desB30 human insulin  
A10C, B3G, B4C, desB30 human insulin  
A10C, B3H, B4C, desB30 human insulin  
A10C, B3K, B4C, desB30 human insulin  
30 A10C, B3P, B4C, desB30 human insulin  
A10C, B3S, B4C, desB30 human insulin  
A10C, B3Y, B4C, desB30 human insulin  
A8H, A14E, A21C, B25H, B26C, desB30 human insulin  
A10C, A14E, B4C, B25N, B27E, desB30 human insulin  
35 A10C, A14E, B4C, B25N, desB27, desB30 human insulin

- A10C, A14E, B4C, B25A, desB30 human insulin  
A21C, B10E, B25C, desB30 human insulin  
A8H, A21C, B10E, B25C, desB30 human insulin  
A8H, A21C, B25C, desB30 human insulin  
5 A10C, B3C, B25H, desB27, desB30 human insulin  
A10C, A21G, B3Q, B4C, B28D, desB30 human insulin  
A10C, B4C, B25H, desB27, desB30 human insulin  
A10C, A21G, B4C, desB30 human insulin  
A8H, A21C, B10E, B26C, desB30 human insulin  
10 A21C, B10E, B26C, desB30 human insulin  
A8H, A21C, B26C, desB30 human insulin  
A10C, A14E, B4C, B16H, B25H, desB30 human insulin  
A10C, A14E, B2C, B16H, B25H, desB30 human insulin  
A10C, A14E, B1C, B16H, B25H, desB30 human insulin  
15 A10C, A14E, B2C, B25A, desB30 human insulin

In one embodiment, an insulin analogue according to the invention is selected from the group consisting of:

- A10C, A14E, B1C, B16H, B25H, desB30 human insulin  
20 A10C, A14E, B1C, B25H, desB30 human insulin  
A10C, A14E, B2C, B16H, B25H, desB30 human insulin  
A10C, A14E, B2C, B25A, desB30 human insulin  
A10C, A14E, B2C, B25H, desB30 human insulin  
A10C, A14E, B3C, B16H, B25H, desB30 human insulin  
25 A10C, A14E, B3C, B25H, desB27, desB30 human insulin  
A10C, A14E, B3C, B25H, desB30 human insulin  
A10C, A14E, B3C, desB27, desB30 human insulin  
A10C, A14E, B4C, B16H, B25H, desB30 human insulin  
A10C, A14E, B4C, B25A, desB30 human insulin  
30 A10C, A14E, B4C, B25H, B28E, desB30 human insulin  
A10C, A14E, B4C, B25H, desB27, desB30 human insulin  
A10C, A14E, B4C, B25H, desB30 human insulin  
A10C, A14E, B4C, B25N, B27E, desB30 human insulin  
A10C, A14E, B4C, B25N, desB27, desB30 human insulin  
35 A10C, A14E, desB1, B4C, B25H, desB30 human insulin

A10C, A14H, B4C, B25H, desB30 human insulin  
A10C, B3C, B25H, desB27, desB30 human insulin  
A10C, B3C, B25H, desB30 human insulin  
A10C, B4C, B25H, desB27, desB30 human insulin  
5 A10C, B4C, B25H, desB30 human insulin

In one embodiment, an insulin analogue according to the invention is selected from the group consisting of:

A10C, A14E, B1C, B16H, B25H, desB30 human insulin  
10 A10C, A14E, B2C, B16H, B25H, desB30 human insulin  
A10C, A14E, B3C, B16H, B25H, desB30 human insulin  
A10C, A14E, B4C, B16H, B25H, desB30 human insulin

In one embodiment, an insulin analogue according to the invention is selected from 15 the group consisting of:

A10C, A21G, B1G, B3C, B27E, desB30 human insulin  
A10C, A21G, B1G, B3E, B4C, B27E, desB30 human insulin  
A10C, A21G, B2C, B3E, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, B2C, B3E, B28E, desB30 human insulin  
20 A10C, A21G, B3C, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, B3C, B28E, desB30 human insulin  
A10C, A21G, B3E, B4C, B22E, B28E, desB30 human insulin  
A10C, A21G, B3E, B4C, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, B3E, B4C, B28E, desB30 human insulin  
25 A10C, A21G, B3E, B4C, desB24, B28E, desB30 human insulin  
A10C, A21G, B3K, B4C, B28E, desB30 human insulin  
A10C, A21G, B3Q, B4C, B28D, desB30 human insulin  
A10C, A21G, B3Q, B4C, B28E, desB30 human insulin  
A10C, A21G, B4C, B28E, desB30 human insulin  
30 A10C, A21G, B4C, desB30 human insulin  
A10C, A21G, desB1, B2C, B3E, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, desB1, B2C, B3E, B28E, desB30 human insulin  
A10C, A21G, desB1, B3C, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, desB1, B3C, B27E, desB30 human insulin  
35 A10C, A21G, desB1, B3C, B28E, desB30 human insulin

A10C, A21G, desB1, B3E, B4C, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, desB1, B3E, B4C, B28E, desB30 human insulin  
A10C, A21G, desB1, B3Q, B4C, B28E, desB30 human insulin  
A10C, A22K, B3C, desB27, desB30 human insulin  
5 A10C, B1C, B28D, desB30 human insulin  
A10C, B2C, B28D, desB30 human insulin  
A10C, B2C, B3A, desB30 human insulin  
A10C, B2C, B3D, desB30 human insulin  
A10C, B2C, B3E, desB30 human insulin  
10 A10C, B2C, B3F, desB30 human insulin  
A10C, B2C, B3G, desB30 human insulin  
A10C, B2C, B3H, desB30 human insulin  
A10C, B2C, B3I, desB30 human insulin  
A10C, B2C, B3K, desB30 human insulin  
15 A10C, B2C, B3L, desB30 human insulin  
A10C, B2C, B3M, desB30 human insulin  
A10C, B2C, B3P, desB30 human insulin  
A10C, B2C, B3Q, desB30 human insulin  
A10C, B2C, B3R, desB30 human insulin  
20 A10C, B2C, B3S, desB30 human insulin  
A10C, B2C, B3T, desB30 human insulin  
A10C, B2C, B3V, desB30 human insulin  
A10C, B2C, B3W, desB30 human insulin  
A10C, B2C, B3Y, desB30 human insulin  
25 A10C, B3D, B4C, desB30 human insulin  
A10C, B3G, B4C, desB30 human insulin  
A10C, B3H, B4C, desB30 human insulin  
A10C, B3K, B4C, desB30 human insulin  
A10C, B3P, B4C, desB30 human insulin  
30 A10C, B3Q, B4C, desB30 human insulin  
A10C, B3R, B4C, desB30 human insulin  
A10C, B3S, B4C, desB30 human insulin  
A10C, B3T, B4C, desB30 human insulin  
A10C, B3V, B4C, desB30 human insulin  
35 A10C, B3Y, B4C, desB30 human insulin

A10C, B4C, B28D human insulin  
A10C, B4C, B28D, desB30 human insulin

In one embodiment an insulin analogue according to the invention also comprises a

5 C-peptide connecting the C-terminus of the B-chain with the N-terminus of the A-chain (to form a so called single-chain insulin analogue). In one embodiment of the invention, the parent insulin is selected from the group consisting of single chain insulin analogues. In one embodiment of the invention, the parent insulin is selected from the group consisting of single chain insulin analogues listed in WO2007096332, WO2005054291 or WO2008043033,

10 which patents are herein specifically incorporated by reference.

The production of polypeptides, e.g., insulins, is well known in the art. An insulin analogue according to the invention may for instance be produced by classical peptide synthesis, e.g., solid phase peptide synthesis using t-Boc or Fmoc chemistry or other well established techniques, see, e.g., Greene and Wuts, "Protective Groups in Organic Synthesis",

15 John Wiley & Sons, 1999. The insulin analogue may also be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the analogue and capable of expressing the insulin analogue in a suitable nutrient medium under conditions permitting the expression of the insulin analogue. Several recombinant methods may be used in the production of human insulin and insulin analogues. Three non-limiting examples of methods which may be used in the production of insulin in microorganisms such as, e.g., *Escherichia coli* and *Saccharomyces cerevisiae* are, e.g., disclosed in WO2008034881.

20 Typically, the insulin analogue is produced by expressing a DNA sequence encoding the insulin analogue in question or a precursor thereof in a suitable host cell by well known technique as disclosed in e.g. EP 1,246,845 or WO2008034881 both of which patents are

25 herein specifically incorporated by reference.

The insulin analogue may be expressed with an N-terminal extension as disclosed in EP 1,246,845. After secretion to the culture medium and recovery, the insulin precursor will be subjected to various in vitro procedures to remove the possible N-terminal extension sequence and connecting peptide to give the insulin analogue. Such methods include enzymatic conversion by means of trypsin or an *Achromobacter lyticus* protease in the presence of an L-threonine ester followed by conversion of the threonine ester of the insulin analogue into the insulin analogue by basic or acid hydrolysis as described in US patent specification No. 4,343,898 or 4,916,212

Examples of N-terminal extensions of the type suitable in the present invention are disclosed in U.S. Patent No. 5,395,922 and EP patent No. 765,395 both of which patents are herein specifically incorporated by reference.

For insulin analogues comprising non-natural amino acid residues, the recombinant 5 cell should be modified such that the non-natural amino acids are incorporated into the analogue, for instance by use of tRNA mutants. Hence, briefly, the insulin analogues according to the invention are prepared analogously to the preparation of known insulin analogues.

The present invention is also related to nucleic acid sequences which code for the claimed insulin analogues. In a further embodiment the present invention is related to vectors 10 containing such nucleic acid sequences and host cells containing such nucleic acid sequences or vectors.

In still a further embodiment, the invention relates to a process for producing an insulin analogue comprising:

- (i) culturing a host cell comprising a nucleic acid sequence encoding an insulin precursor;
- 15 (ii) isolating the insulin precursor from the culture medium and
- (iii) converting the insulin precursor into an insulin analogue of the invention by in vitro enzymatic conversion.

In still a further embodiment, the invention relates to a process for producing an insulin analogue comprising:

- 20 (i) culturing a host cell comprising a nucleic acid sequence encoding an insulin precursor;
- (ii) isolating the insulin precursor from the culture medium and
- (iii) converting the insulin precursor into an insulin analogue of the invention.

In one embodiment of the present invention the host cell is a yeast host cell and in a further embodiment the yeast host cell is selected from the genus *Saccharomyces*. In a further embodiment the yeast host cell is selected from the species *Saccharomyces cerevisiae*. 25

In one aspect of the invention a method for stabilizing an insulin analogue is obtained which comprises substituting two or more amino acids of the parent insulin with cysteine residues, wherein

- 30 a. the three disulfide bonds of human insulin are retained and
- b. the sites of cysteine substitutions are chosen in such a way that the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin,

thereby creating an insulin analogue comprising one or more additional disulfide bonds not 35 present in human insulin.

It is apparent from the description how to obtain an insulin analogue according to the invention. The person skilled in the art thus knows when reading the description how to modify human insulin or desB30 human insulin in such a way that the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for 5 the formation of one or more additional disulfide bonds not present in human insulin in addition to the three disulfide bonds of human insulin.

## PHARMACEUTICAL COMPOSITIONS

Another object of the present invention is to provide a pharmaceutical formulation comprising an insulin analogue according to the present invention which is present in a concentration 10 from 0.1 mg/ml to 500 mg/ml, and wherein said formulation has a pH from 2.0 to 10.0. The formulation may further comprise protease inhibitor(s), a buffer system, preservative(s), tonicity agent(s), chelating agent(s), stabilizers and surfactants. In one embodiment of the invention the pharmaceutical formulation is an aqueous formulation, i.e. formulation comprising water.

15 In another embodiment the pharmaceutical formulation is a dried formulation (e.g. freeze-dried or spray-dried) ready for use without any prior dissolution.

Pharmaceutical compositions containing an insulin analogue according to the present invention may be administered to a patient in need of such treatment at several sites, for example, at topical sites, for example, skin and mucosal sites, at sites which bypass absorption, for example, administration in an artery, in a vein, in the heart, and at sites which involve 20 absorption, for example, administration in the skin, under the skin, in a muscle or in the abdomen.

Administration of pharmaceutical compositions according to the invention may be through several routes of administration, for example, lingual, sublingual, buccal, in the 25 mouth, oral, in the stomach and intestine, nasal, pulmonary, for example, through the bronchioles and alveoli or a combination thereof, epidermal, dermal, transdermal, vaginal, rectal, ocular, for examples through the conjunctiva, uretal, and parenteral to patients in need of such a treatment.

Compositions of the current invention may be administered in several dosage forms, 30 for example, as solutions, suspensions, emulsions, microemulsions, multiple emulsion, foams, salves, pastes, plasters, ointments, tablets, coated tablets, rinses, capsules, for example, hard gelatine capsules and soft gelatine capsules, suppositories, rectal capsules, drops, gels, sprays, powder, aerosols, inhalants, eye drops, ophthalmic ointments, ophthalmic rinses, vaginal pessaries, vaginal rings, vaginal ointments, injection solution, in situ

transforming solutions, for example in situ gelling, in situ setting, in situ precipitating, in situ crystallization, infusion solution, and implants.

For parenteral administration, an insulin analogue of this invention is formulated 5 analogously with the formulation of known insulins. Furthermore, for parenterally administration, an insulin analogue of this invention is administered analogously with the administration of known insulins and the physicians are familiar with this procedure.

Parenteral administration can be performed by means of a syringe, optionally a pen-like syringe. Alternatively, parenteral administration can be performed by means of an infusion 10 pump.

Injectable compositions containing an insulin analogue of this invention can be prepared using the conventional techniques of the pharmaceutical industry which involve dissolving and mixing the ingredients as appropriate to give the desired end product. Thus, according to one procedure, an insulin analogue of this invention is dissolved in an amount of water which is 15 somewhat less than the final volume of the composition to be prepared. An isotonic agent, a preservative and a buffer is added as required and the pH value of the solution is adjusted, if necessary, using an acid, for example, hydrochloric acid, or a base, for example, aqueous sodium hydroxide, as needed. Finally, the volume of the solution is adjusted with water to give the desired concentration of the ingredients.

More precisely, an insulin analogue preparation of this invention, for example a solution or suspension, may be prepared by dissolving a compound of this invention in an aqueous medium at slightly acidic conditions, for example, in a concentration in the range from about 240 to about 2400 nmole/ml. The aqueous medium is made isotonic, for example, with sodium chloride or glycerol. Furthermore, the aqueous medium may contain buffers such as 20 acetate or citrate, preservatives such as m-cresol or phenol and zinc ions, for example, in a concentration of up to about 20 µg of Zn<sup>++</sup> per unit of insulin activity. The pH value of the solution is adjusted towards neutrality without getting too close to the isoelectric point of the compound of this invention in order to avoid precipitation. The pH value of the final insulin 25 preparation depends upon which compound of this invention is used, the concentration of zinc ions and the concentration of the compound of this invention. The insulin analogue preparation is made sterile, for example, by sterile filtration.

Formulations intended for oral use may be prepared according to any known method, and such formulations may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents, and preserving agents in order to 30 provide pharmaceutically elegant and palatable preparations. Tablets may contain the active

ingredient in a mixture with non-toxic pharmaceutically-acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as mannitol, maltodextrin, kaolin, calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch; binding agents, for example, starch, gelatine, polymers or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration or release of the therapeutically active polypeptide.

5 The orally administerable formulations of the present invention may be prepared and  
10 administered according to methods well known in pharmaceutical chemistry, see Remington's Pharmaceutical Sciences, 17<sup>th</sup> ed. (A. Osol ed., 1985).

The insulin analogue preparations of this invention are used similarly to the use of the known insulin preparations.

15 The amount of a compound of this invention to be administered, the determination of how frequently to administer a compound of this invention, and the election of which compound or compounds of this invention to administer, optionally together with another antidiabetic compound, is decided in consultation with a practitioner who is familiar with the treatment of diabetes.

20 In one aspect, the insulin analogue according to the invention is administered orally.  
In one aspect, the insulin analogue according to the invention is administered parentally.

In another embodiment, the present invention relates to an insulin analogue according to the invention for use as a medicament.

25 In one embodiment, an insulin analogue according to the invention is used for the preparation of a medicament for the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance and type 1 diabetes.

In another embodiment, an insulin analogue according to the invention is used as a medicament for delaying or preventing disease progression in type 2 diabetes.

30 In one embodiment of the invention, the insulin analogue according to the invention is for use as a medicament for the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes or for delaying or preventing disease progression in type 2 diabetes.

In a further embodiment of the invention, a method for the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes or for delaying or preventing disease progression in type 2 diabetes, the method comprising administering to

a patient in need of such treatment an effective amount for such treatment of an insulin analogue according to the invention, is provided.

The term "diabetes" includes type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia.

5 The term "treatment" of a disease includes treatment, prevention or alleviation of the disease.

**The following is a list of aspects further describing the invention:**

- 10 1. An insulin analogue having two or more cysteine substitutions and at least one amino acid residue which is substituted with an amino acid which is not a cysteine, where the three disulfide bonds of human insulin are retained, and  
the sites of cysteine substitutions are chosen in such a way that the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for  
15 the formation of one or more additional disulfide bonds not present in human insulin.
2. An insulin analogue according to aspect 1, wherein the sites of cysteine substitutions are chosen in such a way that  
(1) the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds  
20 not present in human insulin, and  
(2) the human insulin analogue retains the desired biological activities associated with human insulin.
3. An insulin analogue according to aspect 1 or 2, wherein the sites of cysteine substitutions are chosen in such a way that  
25 (1) the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin,  
(2) the human insulin analogue retains the desired biological activities associated with human insulin, and  
30 (3) the human insulin analogue has increased physical stability relative to human insulin and/or parent insulin
4. An insulin analogue according to any one of the preceding aspects, wherein the sites of cysteine substitutions are chosen in such a way that

(1) the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin,

5 (2) the human insulin analogue retains the desired biological activities associated with human insulin, and

(3) the human insulin analogue is stabilized against proteolytic degradation.

5. An insulin analogue according to any one of the preceding aspects, wherein at least one amino acid residue in a position selected from the group consisting of A9, A10, A11 and A12 of the A-chain is substituted with a cysteine, at least one amino acid residue in a position selected from the group consisting of B1, B2, B3, B4, B5 and B6 of the B-chain is substituted with a cysteine, at least one amino acid residue is substituted with an amino acid which is not a cysteine and optionally the amino acid in position B30 is deleted.

10 6. An insulin analogue according to any one of the preceding aspects, to the extend possible, wherein the amino acid residue in position A10 of the A-chain is substituted with a cysteine, the amino acid residue in a position selected from the group consisting of B1, B2, B3 and B4 of the B-chain is substituted with a cysteine, and optionally the amino acid in position B30 is deleted.

15 7. An insulin analogue according to any one of the preceding aspects, to the extend possible, wherein the amino acid residue in position A10 of the A-chain is substituted with a cysteine, the amino acid residue in a position selected from the group consisting of B3 and B4 of the B-chain is substituted with a cysteine, and optionally the amino acid in position B30 is deleted.

20 8. An insulin analogue according to any one of the preceding aspects, to the extend possible, wherein the amino acid residue in position A10 of the A-chain is substituted with a cysteine, and amino acid in position B3 of the B-chain is substituted with a cysteine, and optionally the amino acid in position B30 is deleted.

25 9. An insulin analogue according to any one of the preceding aspects, to the extend possible, wherein the amino acid residue in position A10 of the A-chain is substituted with a cysteine, the amino acid in position B4 of the B-chain is substituted with a cysteine, and optionally the amino acid in position B30 is deleted.

30 10. An insulin analogue according to any one of the preceding aspects wherein the amino acid residue in position A21 of the A-chain is substituted with a cysteine, the amino acid residue in a position selected from the group consisting of B25 and B26 of the B-chain is substituted with a cysteine, and optionally the amino acid in position B30 is deleted

11. An insulin analogue according to any one of the preceding aspects, to the extend possible, wherein one or more additional disulfide bonds are obtained between the A-chain and the B-chain
12. An insulin analogue according to any one of the preceding aspects, to the extend possible, wherein one or more additional disulfide bonds are obtained between the A-chain and the B-chain
- 5 13. An insulin analogue according to any one of the preceding aspects, to the extend possible, wherein at least one additional disulfide bond is connecting two cysteines in the A-chain or connecting two cysteines in the B-chain.
- 10 14. An insulin analogue according to any one of the preceding aspects, to the extend possible, wherein the receptor binding to the insulin receptor is at least 1% of the receptor binding of human insulin to the insulin receptor.
- 15 15. An insulin analogue according to any one of the preceding aspects, to the extend possible, which has improved physical stability relative to the parent insulin.
16. An insulin analogue according to any one of the preceding aspects, to the extend possible, wherein the amino acid in position B30 is deleted.
17. An insulin analogue according to any one of the preceding aspects, to the extend possible, wherein at least one additional disulfide bond is connecting two cysteines in the A-chain or two cysteines in the B-chain
- 20 18. An insulin analogue according to any one of the preceding aspects, to the extend possible, which has two cysteine substitutions.
19. An insulin analogue according to any one of the preceding aspects, to the extend possible, which is selected from the group consisting of:
  - A10C, A14E, B1C, B16H, B25H, desB30 human insulin,
  - 25 A10C, A14E, B1C, B25H, desB30 human insulin,
  - A10C, A14E, B2C, B16H, B25H, desB30 human insulin,
  - A10C, A14E, B2C, B25A, desB30 human insulin,
  - A10C, A14E, B2C, B25H, desB30 human insulin,
  - A10C, A14E, B3C, B16H, B25H, desB30 human insulin,
  - 30 A10C, A14E, B3C, B25H, desB27, desB30 human insulin,
  - A10C, A14E, B3C, B25H, desB30 human insulin,
  - A10C, A14E, B3C, desB27, desB30 human insulin,
  - A10C, A14E, B4C, B16H, B25H, desB30 human insulin,
  - A10C, A14E, B4C, B25A, desB30 human insulin,
  - 35 A10C, A14E, B4C, B25H, B28E, desB30 human insulin,

- A10C, A14E, B4C, B25H, desB27, desB30 human insulin,  
A10C, A14E, B4C, B25H, desB30 human insulin,  
A10C, A14E, B4C, B25N, B27E, desB30 human insulin,  
A10C, A14E, B4C, B25N, desB27, desB30 human insulin,  
5 A10C, A14E, desB1, B4C, B25H, desB30 human insulin,  
A10C, A14H, B4C, B25H, desB30 human insulin,  
A10C, B3C, B25H, desB27, desB30 human insulin,  
A10C, B3C, B25H, desB30 human insulin,  
A10C, B4C, B25H, desB27, desB30 human insulin,  
10 A10C, B4C, B25H, desB30 human insulin,  
A10C, A14E, B1C, B16H, B25H, desB30 human insulin,  
A10C, A14E, B2C, B16H, B25H, desB30 human insulin,  
A10C, A14E, B3C, B16H, B25H, desB30 human insulin, and  
A10C, A14E, B4C, B16H, B25H, desB30 human insulin.
- 15 20. An insulin analogue according to any one of the preceding aspects, to the extend possible, which is selected from the group consisting of:  
A10C, A21G, B1G, B3C, B27E, desB30 human insulin  
A10C, A21G, B1G, B3E, B4C, B27E, desB30 human insulin  
A10C, A21G, B2C, B3E, B27E, B28K, desB29, desB30 human insulin  
20 A10C, A21G, B2C, B3E, B28E, desB30 human insulin  
A10C, A21G, B3C, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, B3C, B28E, desB30 human insulin  
A10C, A21G, B3E, B4C, B22E, B28E, desB30 human insulin  
A10C, A21G, B3E, B4C, B27E, B28K, desB29, desB30 human insulin  
25 A10C, A21G, B3E, B4C, B28E, desB30 human insulin  
A10C, A21G, B3E, B4C, desB24, B28E, desB30 human insulin  
A10C, A21G, B3K, B4C, B28E, desB30 human insulin  
A10C, A21G, B3Q, B4C, B28D, desB30 human insulin  
A10C, A21G, B3Q, B4C, B28E, desB30 human insulin  
30 A10C, A21G, B4C, B28E, desB30 human insulin  
A10C, A21G, B4C, desB30 human insulin  
A10C, A21G, desB1, B2C, B3E, B27E, B28K, desB29, desB30 human insulin  
A10C, A21G, desB1, B2C, B3E, B28E, desB30 human insulin  
A10C, A21G, desB1, B3C, B27E, B28K, desB29, desB30 human insulin  
35 A10C, A21G, desB1, B3C, B27E, desB30 human insulin

- A10C, A21G, desB1, B3C, B28E, desB30 human insulin
- A10C, A21G, desB1, B3E, B4C, B27E, B28K, desB29, desB30 human insulin
- A10C, A21G, desB1, B3E, B4C, B28E, desB30 human insulin
- A10C, A21G, desB1, B3Q, B4C, B28E, desB30 human insulin
- 5 A10C, A22K, B3C, desB27, desB30 human insulin
- A10C, B1C, B28D, desB30 human insulin
- A10C, B2C, B28D, desB30 human insulin
- A10C, B2C, B3A, desB30 human insulin
- A10C, B2C, B3D, desB30 human insulin
- 10 A10C, B2C, B3E, desB30 human insulin
- A10C, B2C, B3F, desB30 human insulin
- A10C, B4C, B28D human insulin, and
- A10C, B4C, B28D, desB30 human insulin
21. A method for stabilizing an insulin comprising substituting two or more amino acids of
- 15 human insulin or desB30 human insulin with cysteine residues and at least one amino acid residue with an amino acid which is not a cysteine, wherein
- a. the three disulfide bonds of human insulin are retained and
- b. the sites of cysteine substitutions are chosen in such a way that the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue
- 20 to allow for the formation of one or more additional disulfide bonds not present in human insulin,
- thereby creating an insulin analogue comprising one or more additional disulfide bonds not present in human insulin.
22. A pharmaceutical composition comprising a biologically active amount of the insulin ana-
- 25 logue according to any of the aspects 1-20 and a pharmaceutically acceptable carrier.
23. A pharmaceutical composition according to aspect 22 which further comprises a pharmaceutically acceptable carrier and/or excipient, and optionally an adjuvant.
24. A method for the treatment of diabetes mellitus in a subject comprising administering to a subject an insulin analogue according to any of the aspects 1-20 or a pharmaceutical composition according to any of the aspects 22-23.
- 30
25. A method of reducing the blood glucose level in mammals by administrating to a patient in need of such treatment a therapeutically active dose of an insulin analogue according to any of the aspects 1-20 or a pharmaceutical composition according to any of the aspects 22-23.
- 35 26. Method according to aspect 24-25 being an oral administration.

27. Method according to aspect 24-25 being parenteral administration.
28. Method according to aspect 24-25 being intratracheal administration.
29. An insulin analogue according to any of the aspects 1-20 for use as a pharmaceutical in the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance
- 5 and type 1 diabetes.
30. An insulin analogue according to any of the aspects 1-20 for use as a pharmaceutical in delaying or preventing disease progression in type 2 diabetes.
31. A nucleic acid sequence encoding an insulin analogue according to any of the aspects 1-20, a derivative thereof, a partial sequence thereof, a degenerated sequence thereof or a sequence which hybridises thereto under stringent conditions.
- 10 32. A nucleic acid sequence encoding a precursor of an insulin analogue according to any of the aspects 1-20, a derivative thereof, a partial sequence thereof, a degenerated sequence thereof or a sequence which hybridises thereto under stringent conditions.
33. An expression vector comprising a nucleic acid sequence according to aspect 31 or 32.
- 15 34. A host cell comprising an expression vector according to aspect 33.
35. A method of producing an insulin analogue comprising the step of cultivating the host cell of aspect 34.
36. A method of preparing an insulin analogue according to any of the aspects 1-20 wherein the substitution of amino acids is carried out by site-directed mutagenesis.
- 20 37. A process for preparing a pharmaceutical composition according to any of the aspects 22-23 comprising mixing an insulin analogue according to any of the aspects 1-20 with pharmaceutically acceptable substances and/or excipients.
38. A pharmaceutical composition obtainable by the process according to aspect 37.

25

*All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).*

30

*All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.*

*The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should*

be construed as indicating any non-claimed element as essential to the practice of the invention.

5 The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability, and/or enforceability of such patent documents.

This invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law.

## EXAMPLES

10 The following examples are offered by way of illustration, not by limitation.

The abbreviations used herein are the following:  $\gamma$ Glu is gamma L-glutamyl, HCl is hydrochloric acid, MeCN is acetonitrile, OEG is [2-(2-aminoethoxy)ethoxy]ethylcarbonyl, RPC is reverse phase chromatography, RT is room temperature, TFA is trifluoroacetic acid,

15

The following examples and general procedures refer to intermediate compounds and final products identified in the specification and in the synthesis schemes. The preparation of the compounds of the present invention is described in detail using the following examples, but the chemical reactions described are disclosed in terms of their general applicability to the preparation of compounds of the invention. Occasionally, the reaction may not be applicable as described to each compound included within the disclosed scope of the invention. The compounds for which this occurs will be readily recognised by those skilled in the art. In these cases the reactions can be successfully performed by conventional modifications known to those skilled in the art, that is, by appropriate protection of interfering groups, 20 by changing to other conventional reagents, or by routine modification of reaction conditions. Alternatively, other reactions disclosed herein or otherwise conventional will be applicable to the preparation of the corresponding compounds of the invention. In all preparative methods, all starting materials are known or may easily be prepared from known starting materials. All temperatures are set forth in degrees Celsius and unless otherwise indicated, all parts and 25 percentages are by weight when referring to yields and all parts are by volume when referring to solvents and eluents.

Construction of vectors, yeast expression, processing and purification of insulin analogues can be done using the standard techniques readily recognised by those skilled in the

art. One non-limiting example of preparation of insulin analogues (general procedure (A)) was described previously (*Glendorf, T., Sørensen, A.R., Nishimura, E., Pettersson, I. and Kjeldsen, T. Importance of the Solvent-Exposed Residues of the Insulin B Chain  $\alpha$ -Helix for Receptor Binding. Biochemistry 2008, 47, 4743-4751*). Briefly, mutations are introduced to 5 insulin coding vectors using overlap extension PCR. Insulin analogues are expressed as pro-insulin-like fusion proteins, with an Ala-Ala-Lys mini C-peptide in *Saccharomyces cerevisiae* strain MT663. The single-chain precursors are enzymatically converted into two-chain desB30 analogues using *A. lyticus* endoprotease. Full conversion to the two-chain desB30 analogue is verified by MALDI-TOF MS, and its purity is measured by RP-HPLC at both 10 acidic and neutral pH.

**Purification:**

The compounds of the invention can be purified by employing one or more of the following procedures which are typical within the art. These procedures can - if needed - be 15 modified with regard to gradients, pH, salts, concentrations, flow, columns and so forth. Depending on factors such as impurity profile, solubility of the insulins in question etcetera, these modifications can readily be recognised and made by a person skilled in the art.

Purification of the insulin analogues is performed in one and/or two steps:

1) acidified and clarified culture supernatant are captured by adsorption to a cation 20 exchange column and/or  
2) insulin analogues are purified by preparative reverse phase high pressure liquid chromatography on a C18 silica column with for example an ethanol/water gradient in phosphate buffer at pH 3.

25 After neutral HPLC or anion exchange chromatography, the compounds are de-salting, e.g. by size exclusion chromatography, precipitated at isoelectric pH, or desalting by acidic HPLC.

After acidic HPLC or desalting, the compounds are isolated by lyophilisation of the 30 pure fractions.

**Typical purification procedures:**

The HPLC system is a Gilson system consisting of the following: Model 215 Liquid handler, Model 322-H2 Pump and a Model 155 UV Dector. Detection is typically at 210 nm and 280 nm.

The Åkta Purifier FPLC system (Amersham Biosciences) consists of the following: Model P-900 Pump, Model UV-900 UV detector, Model pH/C-900 pH and conductivity detector, Model Frac-950 Frction collector. UV detection is typically at 214 nm, 254 nm and 276 nm.

5

**Acidic HPLC:**

**Column:** Macherey-Nagel SP 250/21 Nucleusil 300-7 C4

**Flow:** 8 ml/min

**Buffer A:** 0.1% TFA in acetonitrile

10 **Buffer B:** 0.1% TFA in water.

**Gradient:** 0.0 - 5.0 min: 10% A

5.00 – 30.0 min: 10% A to 90% A

30.0 – 35.0 min: 90% A

35.0 – 40.0 min: 100% A

15

**Neutral HPLC:**

**Column:** Phenomenex, Jupiter, C4 5µm 250 x 10.00 mm, 300 Å

**Flow:** 6 ml/min

**Buffer A:** 5 mM TRIS, 7.5 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, pH = 7.3, 20% CH<sub>3</sub>CN

20 **Buffer B:** 60% CH<sub>3</sub>CN, 40% water

**Gradient:** 0 - 5 min: 10% B

5 - 35 min: 10- 60% B

35 - 39 min: 60% B

39 - 40 min: 70% B

25 40 – 43.5 min: 70% B

**Anion exchange chromatography:**

**Column:** RessourceQ, 1 ml

**Flow:** 6 ml/min

30 **Buffer A:** 0.09% NH<sub>4</sub>HCO<sub>3</sub>, 0.25% NH<sub>4</sub>OAc, 42.5% ethanol pH 8.4

**Buffer B:** 0.09% NH<sub>4</sub>HCO<sub>3</sub>, 2.5% NH<sub>4</sub>OAc, 42.5% ethanol pH 8.4

**Gradient:** 100% A to 100% B during 30 column volumes

**Desalting:**

35 **Column:** HiPrep 26/10

**Flow:** 10 ml/min, 6 column volumes  
**Buffer:** 10 mM NH<sub>4</sub>HCO<sub>3</sub>

**Preparation of full length human insulin analogues (coupling of Thr to position B29):**

5

0.23 g L-Threonine methyl ester is dissolved in water (1 mL) and added N-methylpyrrolonine-2-one (NMP) and 200 mg insulin analogue is added. The resulting pH (8.2) is adjusted to pH 6.6 with aqueous acetic acid. ALP III Sepharose 4 fast flow (Novo Nordisk) is added to the mixture and the mixture is gently stirred at room temperature for 3 hours. pH is adjusted to 1.5 with hydrochloric acid and the mixture is filtered. Acetonitrile (2 mL) is added to the filtrate and pH is adjusted to 7.5 with 1 N sodium hydroxide. The insulin analogue with B30T methylester is purified by HPLC using a Phenomenex, Gemini, 5 $\mu$ , C18, 110 Å, 250x30 cm column and the following eluents and gradients:

15           Flow:           20 ml/min  
              Eluents:        A: 20% CH<sub>3</sub>CN 10mM TRIS + 15mM (NH<sub>4</sub>)SO<sub>4</sub> pH = 7.3  
                                 B: 80% CH<sub>3</sub>CN, 20 % water  
              Gradient:       0-7.5 min:    10% B,  
                                 7.5 – 47.5 min: 10% B to 60% B  
20            47.5 -47.5 min: 60% B  
                                 47.5-48 min: 60% B to 100% B  
                                 48-50 min:    100% B  
                                 50-53 min:    10% B

25           Pure fractions are pooled and pH is adjusted to 1.5 with 1N hydrochloric acid and desalted on a Phenomenex, Gemini, 5 $\mu$ , C18, 110 Å, 250x30 cm column using the following eluents and gradients:

30           Flow:           20 ml/min'  
              Eluents:        A: 0,1% Trifluoroacetic acid in water  
                                 B: 0,1% Trifluoroacetic acid in acetonitrile  
              Gradient:       0-7.5 min:    0% B,  
                                 7.5 – 27.5 min: 0% B to 60% B,  
                                 27.5 -32.5 min: 60% B  
35           32.5-38 min: 60% B to 100% B

52

38-40 min: 100% B  
40-43 min: 10% B

5 Insulin containing fractions are pooled and lyophilised to afford full length human  
insulin analogues

10 This is dissolved in ice cold 0.1N sodium hydroxide (10 mg/ml) and is allowed to stand for 1 hour at room temperature for 30 minutes. pH is then adjusted to 2.5 with 1N hydrochloric acid and the insulin is purified by HPLC using a Phenomenex, Gemini, 5μ, C18, 110 Å, 250x30 cm column and using the following eluents and gradients:

15 Flow: 20 ml/min'  
Eluents: A: 0,1% Trifluoroacetic acid in water TFA iCH3CN  
B: 0,1% Trifluoroacetic acid in acetonitrile  
Gradient: 0 – 7.5 min: 25% B,  
7.5 – 47.5 min: 25% B to 55% B,  
47.5 -52.5 min: 55% B  
52.5-57.5 min: 55% B to 100% B  
57.5-60 min: 100% B

20 Finally pure fractions are lyophilised.

Alternatively, these analogues may be prepared using the procedure published by J. Markussen: Human Insulin by Tryptic Transpeptidation of Porcine Insulin and Biosynthetic P

25 **Method 1.** Insulin analogues are analyzed by an Alliance HPLC system (Waters, Milford, MA) using a C18 reversed-phase HPLC column. Insulin analogues separation is achieved employing a linear gradient of acetonitrile in phosphate/sulphate buffer.

30 **Column:** ODDMS 120Å, 5 μm, YMC 4x125 mm, FeF Chemicals  
**Flow:** 1 ml/min  
**Buffer A:** 7.8% (w/v) acetonitrile, 2.84% (w/v) sodium sulphate, 0.46% (w/v) phosphoric acid, 0.13% (w/v) ethanolamine  
**Buffer B:** 43.8% (w/w) acetonitrile in water  
**Gradient:** 20% B to 50% B in 20 min, 50% B to 80% B in 5 min  
35 **Temperature:** 50°C

**Method 2;** LC-MS instrumentation consists of Acquity UPLC system (Waters, Milford, MA) and Synapt G2 mass spectrometer (Waters, Milford, MA). Insulin analogues are applied to a 5 C18 reversed-phase HPLC column and analyzed using a linear gradient of acetonitrile in 0.05% trifluoroacetic acid. The flow from HPLC is applied directly to the electrospray interface of the Synapt G2 operating in the positive MS only mode with 2500 V capillary potential, 110 °C source temperature, 250 °C desolvation temperature and cone gass flow (N<sub>2</sub>) of 50 L/h. MS spectra from m/z=100 to m/z=3000 are acquired twice per second. Instrument is 10 calibrated by a standard mixture of NaI prior to analyses and lock spray of leucine enkephalin is applied during LC-MS analyses. Intact insulin masses are reconstructed by BioPharma-Lynx 1.2 (Waters, Milford, MA) using MaxEnt3 algorithm. Orbitrap XL mass spectrometer (Thermo Fisher) can be used instead of Synapt G2. Orbitrap instrument is operated in the positive MS mode with source voltage of 4 kV, source current of 100 µA, sheath gass flow of 15 40, auxilliary gas flow of 10, sweep gas flow of 5, capillary voltage of 20 V. All MS parameters are adjusted during tuning of the instruments for optimal performance and may deviate slightly from those given above. Mass accuracy obtained by this method is better than 10 ppm.

20

**Column:** Acquity BEH C18 1x150 mm, 1.7 µm (Waters)  
**Flow:** 0.1 ml/min  
**Buffer A:** 0.02% (v/v) or 0.05% (v/v) TFA  
**Buffer B:** 0.02% (v/v) or 0.04% (v/v) TFA in acetonitrile  
25 **Gradient:** 5% B for 2 min; 5%B to 50%B in 12 min, 50%B to 90%B in 1 min  
**UV Detection:** 215 nm

**Method 3;** Supernatants from the yeast cultures containing insulin analogues are acidified 30 using 10% TFA solution and spotted onto PAC384 MALDI plate (Bruker Daltonics, Bremen, Germany) containing HCCA matrix spots. Each spot is washed twice using ammonium phosphate/0.1% TFA finishing solution. Samples are analyzed using an Autoflex Tof/Tof MALDI mass spectrometer (Bruker) operated in a linear positive mode and calibrated using a home-made mixture of insulin analogs. This method allows for average mass resolution in the range of intact insulin analogs (5000-6000 Da).

35

The results given in each of the following examples represent an average from multiple measurements and/or in some cases single measurements. In some instances additional measurements have been conducted since filing the first priority application and this could lead to adjustments of the average values, explaining slightly different values in different versions of the application.

5 *Example 1, General procedure (A):*

**A10C, A21G, B3C, B28E, desB30 human insulin**

Method 2; RT=10.1min; Theoretic Mass=5654.43Da; Measured Mass=5654.46Da

10

*Example 2, General procedure (A):*

**A10C, A21G, B4C, B28E, desB30 human insulin**

Method 2: RT=10.1min; Theoretic Mass=5640.42Da; Measured Mass=5640.44Da

15 *Example 3, General procedure (A):*

**A10C, A21G, B3Q, B4C, B28E, desB30 human insulin**

Method 2: RT=10min; Theoretic Mass=5654.43Da; Measured Mass=5654.47Da

*Example 4, General procedure (A):*

20 **A10C, B2C, B3E, desB30 human insulin**

Method 2: RT=10.3min; Theoretic Mass=5709.44Da; Measured Mass=5709.46Da

*Example 5, General procedure (A):*

**A10C, B3T, B4C, desB30 human insulin**

25 Method 2: RT=10.2min; Theoretic Mass=5652.45Da; Measured Mass=5652.48Da

*Example 6, General procedure (A):*

**A10C, B3V, B4C, desB30 human insulin**

Method 2: RT=10.4min; Theoretic Mass=5650.48Da; Measured Mass=5650.49Da

5    *Example 7, General procedure (A):*

**A10C, B3Q, B4C, desB30 human insulin**

*Example 8, General procedure (A):*

**A10C, A21G, B3E, B4C, B28E, desB30 human insulin**

10    Method 2: RT=10min; Theoretic Mass=5655.42Da; Measured Mass=5655.43Da

*Example 9, General procedure (A):*

**A10C, A21G, B3E, B4C, B22E, B28E, desB30 human insulin**

*Example 10, General procedure (A):*

**A10C, A21G, B3E, B4C, desB24, B28E, desB30 human insulin**

15    *Example 11, General procedure (A):*

**A10C, A21G, B3E, B4C, desB27, B28E, desB30 human insulin**

Method 2: RT=10min; Theoretic Mass=5554.37Da; Measured Mass=5554.39Da

*Example 12, General procedure (A):*

**A10C, B2C, B28D, desB30 human insulin**

*Example 13, General procedure (A):*

**A10C, B1C, B28D, desB30 human insulin**

5    *Example 14, General procedure (A):*

**A10C, A21G, B3K, B4C, B28E, desB30 human insulin**

Method 2: RT=9.8min; Theoretic Mass=5654.47Da; Measured Mass=5654.48Da

*Example 15, General procedure (A):*

10    **A10C, A21G, desB1, B3Q, B4C, B28E, desB30 human insulin**

*Example 16, General procedure (A):*

**A10C, A21G, desB1, B3E, B4C, B28E, desB30 human insulin**

15    *Example 17, General procedure (A):*

**A10C, A21G, B2C, B3E, B28E, desB30 human insulin**

*Example 18, General procedure (A):*

**A10C, A21G, desB1, B2C, B3E, B28E, desB30 human insulin**

*Example 19, General procedure (A):*

**A10C, A21G, desB1, B3C, B28E, desB30 human insulin**

*Example 20, General procedure (A):*

5 **A10C, A21G, B2C, B3E, desB27, B28E, desB30 human insulin**

*Example 21, General procedure (A):*

**A10C, A21G, desB1, B2C, B3E, desB27, B28E, desB30 human insulin**

Method 2: RT=10min; Theoretic Mass=5436.29Da; Measured Mass=5436.31Da

10

*Example 22, General procedure (A):*

**A10C, A21G, desB1, B3E, B4C, desB27, B28E, desB30 human insulin**

Method 2: RT=9.9min; Theoretic Mass=5407.3Da; Measured Mass=5407.33Da

15 *Example 23, General procedure (A):*

**A10C, A21G, B3C, desB27, B28E, desB30 human insulin**

*Example 24, General procedure (A):*

**A10C, A21G, desB1, B3C, desB27, B28E, desB30 human insulin**

20 Method 2: RT=9.9min; Theoretic Mass=5406.32Da; Measured Mass=5406.33Da

*Example 25, General procedure (A):*

**A10C, A21G, desB1, B3C, B27E, desB30 human insulin**

*Example 26, General procedure (A):*

**A10C, A21G, B1G, B3C, B27E, desB30 human insulin**

*Example 27, General procedure (A):*

**A10C, A21G, B1G, B3E, B4C, B27E, desB30 human insulin**

5    *Example 28, General procedure (A):*

**A10C, A22K, B3C, desB27, desB30 human insulin**

Method 2: RT=9.6min; Theoretic Mass=5734.52Da; Measured Mass=5734.52Da

*Example 29, General procedure (A):*

**A10C, B2C, B3A, desB30 human insulin**

10

*Example 30, General procedure (A):*

**A10C, B2C, B3R, desB30 human insulin**

*Example 31, General procedure (A):*

15    **A10C, B2C, B3D, desB30 human insulin**

*Example 32, General procedure (A):*

**A10C, B2C, B3Q, desB30 human insulin**

20    *Example 33, General procedure (A):*

**A10C, B2C, B3G, desB30 human insulin**

*Example 34, General procedure (A):*

**A10C, B2C, B3H, desB30 human insulin**

25

*Example 35, General procedure (A):*

**A10C, B2C, B3I, desB30 human insulin**

*Example 36, General procedure (A):*

5 **A10C, B2C, B3L, desB30 human insulin**

*Example 37, General procedure (A):*

**A10C, B2C, B3K, desB30 human insulin**

10 *Example 38, General procedure (A):*

**A10C, B2C, B3M, desB30 human insulin**

*Example 39, General procedure (A):*

**A10C, B2C, B3F, desB30 human insulin**

15

*Example 40, General procedure (A):*

**A10C, B2C, B3P, desB30 human insulin**

*Example 41, General procedure (A):*

20 **A10C, B2C, B3S, desB30 human insulin**

*Example 42, General procedure (A):*

**A10C, B2C, B3T, desB30 human insulin**

25 *Example 43, General procedure (A):*

**A10C, B2C, B3W, desB30 human insulin**

*Example 44, General procedure (A):*

**A10C, B2C, B3Y, desB30 human insulin**

*Example 45, General procedure (A):*

5    **A10C, B2C, B3V, desB30 human insulin**

*Example 46, General procedure (A):*

**A10C, B3R, B4C, desB30 human insulin**

10    *Example 47, General procedure (A):*

**A10C, B3D, B4C, desB30 human insulin**

*Example 48, General procedure (A):*

**A10C, B3G, B4C, desB30 human insulin**

15

*Example 49, General procedure (A):*

**A10C, B3H, B4C, desB30 human insulin**

*Example 50, General procedure (A):*

20    **A10C, B3K, B4C, desB30 human insulin**

*Example 51, General procedure (A):*

**A10C, B3P, B4C, desB30 human insulin**

25

*Example 52, General procedure (A):*

**A10C, B3S, B4C, desB30 human insulin**

*Example 53, General procedure (A):*

**A10C, B3Y, B4C, desB30 human insulin**

5     *Example 54, General procedure (A):*

**A8H, A14E, A21C, B25H, B26C, desB30 human insulin**

*Example 55, General procedure (A):*

**A10C, A14E, B4C, B25H, desB30 human insulin**

10    Method 2: RT=9.2min; Theoretic Mass=5621.42Da; Measured Mass=5621.44Da

*Example 56, General procedure (A):*

**A10C, A14E, B4C, B25H, desB27, desB30 human insulin**

Method 2: RT=9.1min; Theoretic Mass=5520.37Da; Measured Mass=5520.39Da

15

*Example 57, General procedure (A):*

**A10C, A14E, B4C, B25N, B27E, desB30 human insulin**

*Example 58, General procedure (A):*

20    **A10C, A14E, B4C, B25N, desB27, desB30 human insulin**

*Example 59, General procedure (A):*

**A10C, A14E, B4C, B25A, desB30 human insulin**

25    *Example 60, General procedure (A):*

**A10C, B4C, B28D, desB30 human insulin**

Method 2: RT=10min; Theoretic Mass=5683.42Da; Measured Mass=5684.46Da

*Example 61, General procedure (A):*

**A10C, B4C, B25H, desB30 human insulin**

Method 2: RT=9.3min; Theoretic Mass=5655.44Da; Measured Mass=5655.46Da

5

*Example 62, General procedure (A):*

**A10C, A14E, B3C, B25H, desB30 human insulin**

Method 2: RT=9.2min; Theoretic Mass=5635.44Da; Measured Mass=5635.47Da

10 *Example 63, General procedure (A):*

**A10C, B3C, B25H, desB30 human insulin**

Method 2: RT=9.3min; Theoretic Mass=5669.46Da; Measured Mass=5669.49Da

*Example 64, General procedure (A):*

15 **A21C, B10E, B25C, desB30 human insulin**

Method 1: RT=18.4min

Method 3: Average mass, Theoretic= 5641.5 Da , Measured= 5642.6 Da

*Example 65, General procedure (A):*

20 **A8H, A21C, B10E, B25C, desB30 human insulin**

Method 1: RT=17.4min

Method 3: Average mass, Theoretic= 5677.6 Da , Measured= 5677.1 Da

*Example 66, General procedure (A):*

**A8H, A21C, B25C, desB30 human insulin**

25 Method 1: RT=15.6min

Method 3: Average mass, Theoretic= 5685.6 Da , Measured= 5684.8 Da

*Example 67, General procedure (A):*

**A10C, A14E, B3C, B25H, desB27, desB30 human insulin**

Method 2: RT=10min; Theoretic Mass=5534.39Da; Measured Mass=5534.41Da

5    *Example 68, General procedure (A):*

**A10C, B3C, B25H, desB27, desB30 human insulin**

*Example 69, General procedure (A):*

**A10C, A21G, B3Q, B4C, B28D, desB30 human insulin**

10

*Example 70, General procedure (A):*

**A10C, B4C, B25H, desB27, desB30 human insulin**

*Example 71, General procedure (A):*

15    **A10C, A14E, desB1, B4C, B25H, desB30 human insulin**

Method 2: RT=9min; Theoretic Mass=5474.35Da; Measured Mass=5474.37Da

*Example 72, General procedure (A):*

**A10C, A14E, B4C, B25H, B28E, desB30 human insulin**

20    Method 2: RT=9.1min; Theoretic Mass=5653.41Da; Measured Mass=5653.44Da

*Example 73, General procedure (A):*

**A10C, A14H, B4C, B25H, desB30 human insulin**

Method 2: RT=9min; Theoretic Mass=5629.44Da; Measured Mass=5629.46Da

25

*Example 74, General procedure (A):*

**A10C, A14E, B2C, B25H, desB30 human insulin**

Method 2: RT=9.4min; Theoretic Mass=5650.41Da; Measured Mass=5650.43Da

*Example 75, General procedure (A):*

**A10C, A14E, B1C, B25H, desB30 human insulin**

- 5 Method 2: RT=9.6min; Theoretic Mass=5602.41Da; Measured Mass=5602.43Da

*Example 76, General procedure (A):*

**A10C, A21G, B4C, desB30 human insulin**

*Example 77, General procedure (A):*

- 10 **A8H, A21C, B10E, B26C, desB30 human insulin**

Method 1: RT=21.9min

Method 3: Average mass, Theoretic= 5661.6 Da , Measured= 5662.3 Da

*Example 78, General procedure (A):*

- 15 **A21C, B10E, B26C, desB30 human insulin**

Method 1: RT=22.2min

*Example 79, General procedure (A):*

**A8H, A21C, B26C, desB30 human insulin**

- 20 Method 1: RT=19.5min

*Example 80, General procedure (A):*

**A10C, A14E, B4C, B16H, B25H, desB30 human insulin**

- 25 *Example 81, General procedure (A):*

**A10C, A14E, B3C, B16H, B25H, desB30 human insulin**

Method 2: RT=8.6min; Theoretic Mass=5609.43Da; Measured Mass=5609.45Da

*Example 82, General procedure (A):*

**A10C, A14E, B2C, B16H, B25H, desB30 human insulin**

*Example 83, General procedure (A):*

5 **A10C, A14E, B1C, B16H, B25H, desB30 human insulin**

*Example 84, General procedure (A):*

**A10C, A14E, B2C, B25A, desB30 human insulin**

10 *Example 85, General procedure (A):*

**A10C, B4C, B28D human insulin**

Method 2: RT=10min; Theoretic Mass=5784.47Da; Measured Mass=5784.49Da

*Example 86, General procedure (A):*

15 **A10C, A14E, B3C, desB27, desB30 human insulin**

Method 2: RT=10min; Theoretic Mass=5544.4Da; Measured Mass=5544.43Da

*Example 87 Insulin receptor affinity of selected insulin analogues of the invention:*

20 **Insulin Receptor Binding Assay (on solubilised insulin receptor)**

The affinity of the insulin analogue of the invention for the human insulin receptor was determined by a Scintillation Proximity Assay (SPA) (according to Glendorf *et al.* (2008), *Biochemistry*, **47**, 4743-4751). Competition binding experiments were performed in 96-well plates (polystyrene Optiplate-96, PerkinElmer) on an Eppendorf epMotion 5075 robot using solubilized human IR (holoreceptor) semipurified by wheat germ agglutinin purification from baby hamster kidney (BHK) cells, which were stably transfected with the pZem vector containing the human IR-A or IR-B insert. Assays were initiated by making dilution series (eight dilutions, 5-fold each, first dilution 43-fold) of yeast supernatant containing the insulin analogue and a human insulin standard. A reagent mix consisting of SPA beads (SPA PVT Antibody-Binding Beads, Anti-Mouse Reagent Cat. No. RPNC0017, GE Healthcare) resuspended in

binding buffer, anti-IR monoclonal mouse antibody (83-7), solubilized human IR (hIR-A or hIR-B), and [<sup>125</sup>I]A14Tyr-labelled insulin was added to the dilution series of the appropriate samples. The final concentration of [<sup>125</sup>I]A14Tyr-labelled insulin was 7.5 pM, and the buffer consisted of 100 mM HEPES (pH 7.8), 100 mM NaCl, 10 mM MgSO<sub>4</sub>, and 0.025% (v/v)

5 Tween 20. Plates were incubated with gentle shaking for 24 h at room temperature, centrifuged for 2 minutes at 2000 rpm, and counted in a TopCount NXT for 3 min/well. Data from the SPA were analyzed according to the four-parameter logistic model (Vølund, A., (1978), *Biometrics*, **34**, 357-365.) and the affinities of the insulin analogue expressed relative to that of human insulin.

10

#### Preparation of monoclonal mIR antibodies

Specific antibodies (F12 or 83-7) were produced by monoclonal technique: RBF mice were immunized by injecting 50 µg of purified mIR in FCA subcutaneously followed by two injections with 20 µg of mIR in FIA. High responder mice were boosted intravenously with 25 µg 15 of mIR and the spleens were harvested after 3 days. Spleen cells were fused with the myeloma Fox cell line (Köhler, G & Milstein C. (1976), European J. Immunology, 6:511-19; Taggart RT et al (1983), Science 219:1228-30). Supernatants were screened for antibody production in a mIR specific ELISA. Positive wells were cloned and tested in Western blotting.

20

Insulin receptor affinities of insulin analogues according to the invention:

Insulin analogue from example #	Relative Affinity to Human Insulin Receptor A (% HI)
1	32.9
2	135.0
3	32.4
4	120.9
5	49.7
6	2.9
7	39.6
8	50.7
9	3.4

Insulin analogue from example #	Relative Affinity to Human Insulin Receptor A (% HI)
10	35.0
11	23.7
12	116.8
13	48.6
14	67.1
15	39.3
16	37.6
17	80.0
18	67.5
19	29.5
20	49.7
21	69.3
22	20.1
23	20.0
24	17.8
25	29.2
26	24.3
27	24.3
29	109.3
30	95.3
31	107.2
32	115.0
33	123.9
34	96.5
35	37.3
36	72.1
37	42.9
38	78.1
39	75.5

Insulin analogue from example #	Relative Affinity to Human Insulin Receptor A (% HI)
40	37.4
41	136.7
42	95.9
43	49.6
44	45.4
45	62.9
46	61.0
47	151.7
48	117.7
49	73.1
50	156.5
51	104.6
52	119.3
53	11.5
54	.4
55	37.8
56	44.3
57	7.3
58	12.7
59	7.2
60	160.4
61	52.0
62	11.4
63	14.5
64	21.3
65	86.2
66	12.1
67	10.7
68	14.2

Insulin analogue from example #	Relative Affinity to Human Insulin Receptor A (% HI)
69	32.0
70	57.9
71	36.4
72	42.3
73	46.6
74	37.1
75	13.2
76	102.5
77	55.7
78	10.0
79	4.8
80	16.0
81	4.0
82	12.0
83	3.2
84	6.6
85	203.6
86	44.8
A14E, B25H, desB30 human insulin (prior art)	25.0
A14E, B16H, B25H, desB30 human insulin (prior art)	5.4

**Example 88 Degradation of insulin analogues using duodenum lumen enzymes:**

Degradation of insulin analogues using duodenum lumen enzymes (prepared by filtration of  
5 duodenum lumen content) from SPD rats.

The assay was performed by a robot (Gilson liquid handling station) in a 96 well plate (2ml) with 16 wells available for insulin analogues and standards. Insulin analogues ~15  $\mu$ M were incubated with duodenum enzymes in 100 mM Hepes, pH=7.4 at 37°C, samples were taken after 1, 15, 30, 60, 120 and 240 min and reaction quenched by addition of TFA. Concentrations of intact insulin analogues at each point were determined by RP-HPLC. Degradation half time was determined by exponential fitting of the data (for example, single exponential decay, 2 parameters, Sigma Plot version 11, Systat Software) and normalized to half time determined for the reference insulins, or human insulin in each assay. The result is given as the degradation half time for the insulin analogue in rat duodenum divided by the degradation half time of the reference insulin from the same experiment (relative degradation rate).

<b>Insulin analogue from example #</b>	<b>Duodenum Degradation Relative Stability vs. Human Insulin</b>
1	1.5
2	1.7
3	2.2
4	2.2
5	2.2
6	1.1
11	14.3
14	2.8
21	8.8
22	5.0
24	9.4
54	20.9
55	53.6
56	>100
60	3.9
61	9.4

Insulin analogue from example #	Duodenum Degradation Relative Stability vs. Human Insulin
62	68.2
63	7.0
67	>100
71	81.4
72	74.8
73	13.2
74	15.4
75	6.6
81	52.8
85	2.2
86	>100
A14E, B25H, desB30 human insulin (prior art)	11
A14E, B16H, B25H, desB30 human insulin (prior art)	10

**Example 89 Melting point determinations**

*Differential Scanning Calorimetry (DSC).*

Data collection was performed using a VP-DSC differential scanning microcalorimeter

5 (MicroCal, LLC, Northampton, MA). All protein scans (~200  $\mu$ M insulin analogs) were performed with 2 mM phosphate buffer in the reference cell from 10 °C to 110 °C at a scan rate of 1 °C/min and an excess pressure of 0.21 MPa. All samples and references were degassed immediately before use. A buffer-buffer reference scan was subtracted from each sample scan prior to concentration normalization.

**Example 90 Measurement of tendencies of fibrillation****General procedure for Thioflavin T (ThT) fibrillation assay:****Principle:**

- 5 Low physical stability of a peptide may lead to amyloid fibril formation, which is observed as well-ordered, thread-like macromolecular structures in the sample eventually resulting in gel formation. This has traditionally been measured by visual inspection of the sample. However, that kind of measurement is very subjective and depending on the observer. Therefore the application of a small molecule indicator probe is much preferred.
- 10 Thioflavin T (ThT) is such a probe and has a distinct fluorescence signature when binding to fibrils (Naiki et al. Anal. Biochem. **177**, 244-249, 1989; Le-Vine, Methods Enzymol. **309**, 274-284, 1999). The time course for fibril formation can be described by a sigmoidal curve with the following expression (Nielsen et al. Biochemistry **40**, 6036-6046, 2001):

$$F = f_i + m_i t + \frac{f_f + m_f t}{1 + e^{-[(t-t_0)/\tau]}} \text{ Eq. (1)}$$

15

Here, F is the ThT fluorescence at the time t. The constant  $t_0$  is the time needed to reach 50% of maximum fluorescence. The two important parameters describing fibril formation are the lag-time calculated by  $t_0 - 2\tau$  and the apparent rate constant  $k_{app} = 1/\tau$ .

Formation of a partially folded intermediate of the peptide is suggested as a general 20 initiating mechanism for fibrillation. Few of those intermediates nucleate to form a template onto which further intermediates may assemble and the fibrillation proceeds. The lag-time corresponds to the interval in which the critical mass of nucleus is built up and the apparent rate constant is the rate with which the fibril itself is formed.

25 **Sample preparation:**

Samples were prepared freshly before each assay. Each analogue was dissolved in 7 mM sodium phosphate, pH=7.4. Thioflavin T was added to the samples from a stock solution in water to a final concentration of 1  $\mu$ M. Sample aliquots of 200  $\mu$ l were placed in a 96 well microtiter plate (Packard Optiplate™-96, white polystyrene). Usually four replica of each 30 sample (corresponding to one test condition) were placed in one column of wells. The plate was sealed with Scotch Pad (Qiagen).

**Incubation and fluorescence measurements:**

Incubation at given temperature, shaking and measurements of the ThT fluorescence emission were done in either a Fluoroskan Ascent FL or Varioskan fluorescence plate reader (thermo Labsystems). The temperature was adjusted to 37°C. The orbital shaking was adjusted to 960 rpm with an amplitude of 1 mm in all the presented data. Fluorescence 5 measurements were done using excitation through a 444 nm filter and measurement of emission through a 485 nm filter.

Each run was initiated by incubating the plate at the assay temperature for 10 min. The plate was measured every 20 minutes for typically 45 hours. Between each measurement, the plate was shaken and heated as described above.

10

Data handling:

The measurement data points were saved in Microsoft Excel format for further processing and curve drawing and fitting was performed using GraphPad Prism. The background emission from ThT in the absence of fibrils was negligible. The data points are typically a mean of four samples. Only data obtained in the same experiment (i.e. samples on 15 the same plate) are presented in the same graph ensuring a relative measure of fibrillation between the individual samples of one assay rather than comparison between different assays.

The data set may be fitted to Eq. (1). However since the full sigmoidal curves are 20 not usually achieved during the measurement time, the degree of fibrillation is expressed as ThT fluorescence at various time points calculated as the mean of the four samples and shown with the standard deviation.

Typical lag time for human insulin (prior art) is <2h.

Insulin analogue from example #	0 h	2 h	20 h	45 h
human insulin (prior art)	28±1	1567±46	1780±40	1732±48
1	31 + 0.1	25.4 + 1	24.5 + 0.8	26.2 + 1.1
2	32.2 ± 0.8	24.2 ± 1.4	25.5 ± 1.2	27.2 ± 2.8
3	20.7 ± 0.5	18.2 ± 0.6	19.2 ± 0.8	19.8 ± 1
4	16.6 ± 0.1	16.7 ± 0.1	16.9 ± 0.1	16.9 ± 0.2
5	17.6 ± 0.2	17.8 ± 0.2	17.9 ± 0.1	17.9 ± 0.1
6	17.3 ± 0.3	17.4 ± 0.3	17.6 ± 0.4	17.6 ± 0.3
8	34.1±1.2	27.2±2.5	22.4±3.3	20.6±3.3

Insulin analogue from example #	0 h	2 h	20 h	45 h
28	35.8 ± 0.9	29.4 ± 1	27.6 ± 0.8	25 ± 0.7
55	32.5 + 1.3	31 + 0.6	29.4 + 0.4	27.2 + 0.3
56	67.1 + 1.2	65.7 + 3.3	65.8 + 6.7	68.7 + 7.8
60	29 + 1	23.9 + 0.5	23.6 + 2.5	24.6 + 3.2
61	26.2 ± 0.6	22.3 ± 0.3	26.1 ± 0.2	26.5 ± 0.4
62	26.9 + 1	24.1 + 0.5	23.6 + 0.4	25.4 + 0.7
63	32.8 + 0.1	30.7 + 0.2	30 + 0.2	31 + 0.2
67	37.2 ± 0.7	25.9 ± 1.1	24.1 ± 2.7	22.4 ± 2.8
71	30.2±0.6	20.9±0.8	21±0.8	20.1±0.8
72	31.6±1.1	23.4±0.9	22.3±0.7	21.3±0.8
73	35.4±0.6	24.8±0.4	22.9±0.4	21.5±0.4
74	30.5±0.5	24.7±0.3	23.9±0.2	22.8±0.4
75	28.8±1.1	22±0.6	19.9±0.6	18.3±0.7
81	26.6 ± 1.4	20.9 ± 0.2	19.3 ± 0.8	19.2 ± 0.3
85	28.4±0.8	22.8±0.4	23±0.3	22.5±0.3
86	29.1 ± 0.9	21.6 ± 0.3	21.4 ± 0.7	20.4 ± 0.6

It is evident that none of the insulins according to the invention that were tested towards fibrillation in the ThT assay showed any signs of fibrillation as seen by (absence of) increased fluorescence as a function of time. This is very unusual and this emphasizes the 5 utility of the analogues of the invention.

Fibrillation propensities are shown in figure 2

10 **Example 91, Chemical stability of the insulin analogues of the invention:**

Chemical stability of an insulin analogue is assessed after incubating insulin analogue in 2 mM phosphate, pH=7.5 at 37°C for upto 8 weeks. Formation of high molecular weight products (HMWP) is determined by SEC HPLC analysis after 0, 2, 4 and optionally 8 weeks. The results of the SEC method are given as a difference between HMWP formation 15 at 37°C and 5°C start sample as a percentage of total absorbance at 215 nm. Chemical

degradation products are determined by RP HPLC analysis after 0, 2, 4 and optionally 8 weeks. The results of the RP method are given as a difference between chemical degradation observed at 37°C and 5°C start sample as a percentage of total absorbance at 215 nm.

5 SEC-HPLC Method:

Solvent: 500 mM NaCl, 10 mM NaH<sub>2</sub>PO<sub>4</sub>, 5 mM H<sub>3</sub>PO<sub>4</sub>, 50% (v/v) 2-propanol  
Flow: 0.5 ml/min  
Run time: 30 min  
UV Detection: 215 nm  
10 Column: Insulin HMWP column from Waters 7.8x300mm  
Temperature: 50°C

RP-HPLC Method:

Solvent A: 0.09M phosphatbuffer pH 3.6 (di-ammoniumhydrogenphosphat), 10%  
15 MeCN (v/v)  
Solvent B: 80% MeCN (v/v%)  
Flow: 0.3 ml/min  
Runtime: 33 min  
UV Detection: 215 nm  
20 Column: Waters Acquity BEH130 C18 Column 1.7 µm, 150x2.1mm  
Temperature: 50°C

Gradient:

Time, min	Flow, ml/min	%A	%B
0	0.3	95	5
2	0.3	95	5
25	0.3	45	55
27	0.3	20	80
28	0.3	20	80
29	0.3	95	5
33	0.3	95	5

Insulin analogue from Example#	Chemical degradation (%)	HMWP Formation (%) (4weeks 37°C-0weeks (4weeks 37°C- 5°C) 0weeks 5°C)
		# (8weeks 37°C- 0weeks 5°C) values given
1	6.8	0.8
2	19.0	3.6
3	3.6	1.5
4	23.5	19.2
5	4.0	2.7
6	3.0	1.2
8	9.7	2.0
11	8.8	0.5
14	5.5	4.3
21	78.5	33.5
22	19.4	4.8
24	12.5	1.6
55	11.9	0.7 <sup>#</sup>
56	9.8	1.6
60	18.7	15.1
61	4.6	2.7
62	2.4	0.1 <sup>#</sup>
63	4.1	1.2
67	2.4	1.2
71	14.1	0.7
72	9.3	1.0
73	8.2	3.0
74	36.0	7.6 <sup>#</sup>
75	60.9	40.0 <sup>#</sup>
81	1.9	1.2
85	10.2	16.3

Insulin analogue from Example#	Chemical degradation (%)	HMWP Formation (%)
	(%)	(4weeks 37°C-0weeks (4weeks 37°C- 5°C) 0weeks 5°C)
		# (8weeks 37°C- 0weeks 5°C) values given
	86	0.6
B28D human insulin	22.3	2.9
	(prior art)	

It is concluded that analogues with a disulfide to B3 are in general more stable than analogues with a disulfide to B4, and analogues with disulfide to B2 or B1 are less stable.

*Example 92, Hydrophobicity of the insulin analogues of the invention:*

5 The hydrophobicity of an insulin analogue is found by reverse phase HPLC run under isocratic conditions. The elution time of the insulin analogue is compared to that of human insulin (herein designated HI) or another analogue with a known hydrophobicity under the same conditions. The hydrophobicity,  $k'_{rel}$ , is calculated as:  $k'_{rel_{deriv}} = ((t_{deriv} - t_0) / (t_{ref} - t_0)) * k'_{rel_{ref}}$ . Using HI as reference:  $k'_{rel_{ref}} = k'_{rel_{HI}} = 1$ . The void time of the HPLC system,  $t_0$ , is  
10 determined by injecting 5  $\mu$ l of 0.1 mM NaNO<sub>3</sub>. Running conditions:

Column: Lichrosorb RP-C18, 5 $\mu$ m, 4 x 250 mm  
Buffer A: 0.1 M sodium phosphate pH 7.3, 10 vol% CH<sub>3</sub>CN  
Buffer B: 50 vol% CH<sub>3</sub>CN  
15 Injection volume: 5  $\mu$ l  
Run time: max 60 minutes

After running an initial gradient, the isocratic level for running the analogue and reference (for example HI) is chosen, and the elution times of the analogue and reference under isocratic conditions are used in the above equation to calculate  $k'_{rel_{deriv}}$ .  
20

Insulin analogue from Example# k'-rel (human insulin)  
1

0.0627

2	0.0489
3	0.0349
4	0.0467
5	0.1090
6	0.1620
8	0.0136
11	0.0103
14	0.0668
21	0.0053
22	0.0046
24	0.0109
28	0.0810
60	0.0375
A14E, B25H, desB30 (prior art)	0.0649
A14E, B16H, B25H, desB30 (prior art)	0.0331

**Example 93, Rat pharmacokinetics, intravenous rat PK:**

Anaesthetized rats were dosed intravenously (*i.v.*) with insulin analogues at various doses and plasma concentrations of the employed compounds were measured using immunoassays or mass spectrometry at specified intervals for 4 hours or more post-dose. Pharmacokinetic parameters were subsequently calculated using WinNonLin Professional (Pharsight Inc., Mountain View, CA, USA).

10 Non-fasted male Wistar rats (Taconic) weighing approximately 200 gram were used.

Body weight was measured and rats were subsequently anaesthetized with Hypnorm/Dormicum (each compound is separately diluted 1:1 in sterile water and then mixed; prepared freshly on the experimental day). Aanaesthesia was initiated by 2 ml/kg 15 Hypnorm/Doricum mixture sc followed by two maintenance doses of 1 ml/kg sc at 30 min intervals and two maintenance doses of 1 ml/kg sc with 45 min intervals. If required in order

to keep the rats lightly anaesthetised throughout a further dose(s) 1-2 ml/kg sc was supplied. Weighing and initial anaesthesia was performed in the rat holding room in order to avoid stressing the animals by moving them from one room to another.

5 **Example 94, Blood glucose lowering effect, intravenous rat PD:**

Male, fed Wistar rats (250-300 g) were anesthetized using Hypnorm-Dormicum (0.081 mg/ml fentanyl citrate and 1.25 mg/ml Midazolam) 2 ml/kg as a priming dose (time=-35 min) and additional 1 ml/kg to time= -5 min prior to test substance dosing, and then 1 ml/kg every 45 minutes (4 times).

10 The rats were allocated into 5 groups, 4-6 rats in each group being administrated human insulin and insulin analogues were administered in two doses (1.6 nmol/kg and 3.6 nmol/kg). The animals were dosed with an intravenous injection in a tail vein (1 ml/kg) of either vehicle (5 mM phosphate buffer, 140 mM NaCl, 70 ppm polysorbate 20, pH 7.4) or insulins. Blood samples for the determination of whole blood glucose concentration 15 were collected in heparinized 10 µl glass tubes by puncture of the capillary vessels in the tail tip to timepoints before dosing and after dosing. The blood glucose concentrations were measured after dilution in analysis buffer (500 µl) by the immobilized glucose oxidase method using a Biosen autoanalyzer (EKF Diagnostic, Germany).

20 PD profiles are shown in figure 3

**Example 95, Rat pharmacokinetics, rat PK following intraintestinal injection:**

Anaesthetized rats are dosed intraintestinally (into jejunum) with insulin analogues. Plasma concentrations of the employed compounds as well as changes in blood glucose are 25 measured at specified intervals for 4 hours or more post-dosing. Pharmacokinetic parameters are subsequently calculated using WinNonLin Professional (Pharsight Inc., Mountain View, CA, USA).

Male Sprague-Dawley rats (Taconic), weighing 250-300 g, fasted for ~18 h are anesthetized using Hypnorm-Dormicum s.c. (0.079 mg/ml fentanyl citrate, 2.5 mg/ml fluanisone and 1.25 mg/ml midazolam) 2 ml/kg as a priming dose (to timepoint -60 min prior to test substance dosing), 1 ml/kg after 20 min followed by 1 ml/kg every 40 min.

The insulins to be tested in the intraintestinal injection model are formulated according to the following composition (in weight %):

45% Propylene glycol

(Merck)

33% Capmul MCM C10	(Abitec)
11% Poloxamer 407	(BASF)
11% Polyethyleneglycol 3350 Ultra	(Fluka)

5 The amount of added insulin is subtracted equally from Capmul MCM C10, Poloxamer 407 and PEG 3350 and not from propylene glycol in order to keep the amount of propylene glycol independent of the drug load constant at 45%.

The anesthetized rat is placed on a homeothermic blanket stabilized at 37°C. A 20 cm polyethylene catheter mounted a 1-ml syringe is filled with insulin formulation or vehicle.

10 A 4-5 cm midline incision is made in the abdominal wall. The catheter is gently inserted into mid-jejunum ~ 50 cm from the caecum by penetration of the intestinal wall. If intestinal content is present, the application site is moved  $\pm$  10 cm. The catheter tip is placed approx. 2 cm inside the lumen of the intestinal segment and fixed without the use of ligatures. The intestines are carefully replaced in the abdominal cavity and the abdominal wall and skin are

15 closed with autoclips in each layer. At time 0, the rats are dosed via the catheter, 0.4 ml/kg of test compound or vehicle.

Blood samples for the determination of whole blood glucose concentrations are collected in heparinised 10  $\mu$ l capillary tubes by puncture of the capillary vessels in the tail tip.

20 Blood glucose concentrations are measured after dilution in 500  $\mu$ l analysis buffer by the glucose oxidase method using a Biosen autoanalyzer (EKF Diagnostic GmbH, Germany). Mean blood glucose concentration courses (mean  $\pm$  SEM) are made for each compound.

Samples are collected for determination of the plasma insulin concentration. 100  $\mu$ l blood samples are drawn into chilled tubes containing EDTA. The samples are kept on ice until centrifuged (7000 rpm, 4°C, 5 min), plasma is pipetted into Micronic tubes and then frozen at 20°C until assay. Plasma concentrations of the insulin analogues are measured in a immunoassay which is considered appropriate or validated for the individual analogue.

Blood samples are drawn at t=-10 (for blood glucose only), at t=-1 (just before dosing) and at specified intervals for 4 hours or more post-dosing.

**Example 96, Potency of insulin analogues of this invention relative to human insulin, intravenous steady-state clamp.**

Sprague Dawley male rats weighing 238-383 g on the experimental day are used for the clamp experiment. The rats have free access to feed under controlled ambient conditions 5 and are fasted overnight (from 3 pm) prior to the clamp experiment.

Experimental Protocol:

The rats are acclimatized in the animal facilities for at least 1 week prior to the surgical procedure. Approximately 1 week prior to the clamp experiment, Tygon catheters are 10 inserted under halothane anaesthesia into the jugular vein (for infusion) and the carotid artery (for blood sampling) and exteriorised and fixed on the back of the neck. The rats are given Streptocillin vet. (Boehringer Ingelheim; 0.15 ml/rat, i.m.) post-surgically and placed in an animal care unit (25 °C) during the recovery period. In order to obtain analgesia, Anorphin 15 (0.06 mg/rat, s.c.) is administered during anaesthesia and Rimadyl (1.5 mg/kg, s.c.) is administered after full recovery from the anaesthesia (2-3 h) and again once daily for 2 days.

At 7 am on the experimental day overnight fasted (from 3 pm the previous day) rats are weighed and connected to the sampling syringes and infusion system (Harvard 22 Basic pumps, Harvard, and Perfectum Hypodermic glass syringe, Aldrich) and then placed into individual clamp cages where they rest for ca. 45 min before start of experiment. The rats are 20 able to move freely on their usual bedding during the entire experiment and have free access to drinking water. After a 30 min basal period during which plasma glucose levels were measured at 10 min intervals, the insulin analogue to be tested and human insulin (one dose level per rat, n = 6-7 per dose level) are infused (i.v.) at a constant rate for 300 min. Optionally a priming bolus infusion of the insulin analogue to be tested is administered in order to 25 reach immediate steady state levels in plasma. The dose of the priming bolus infusion can be calculated based on clearance data obtained from i.v. bolus pharmacokinetics by a pharmacokinetician skilled in the art. Plasma glucose levels are measured at 10 min intervals throughout and infusion of 20% aqueous glucose is adjusted accordingly in order to maintain euglycaemia. Samples of re-suspended erythrocytes are pooled from each rat and returned 30 in about ½ ml volumes via the carotid catheter.

On each experimental day, samples of the solutions of the individual insulin analogues to be tested and the human insulin solution are taken before and at the end of the clamp experiments and the concentrations of the peptides are confirmed by HPLC. Plasma concentrations of rat insulin and C-peptide as well as of the insulin analogue to be tested and

human insulin are measured at relevant time points before and at the end of the studies. Rats are killed at the end of experiment using a pentobarbital overdose.

**Example 97, Lipogenesis in rat adipocytes**

5 As a measure of *in vitro* potency of the insulins of the invention, lipogenesis can be used.

Primary rat adipocytes are isolated from the epididymal fat pads and incubated with 3H-glucose in buffer containing e.g. 1 % fat free HSA and either standard (human insulin, HI) or insulin of the invention. The labelled glucose is converted into extractable lipids in a 10 dose dependent way, resulting in full dose response curves. The result is expressed as relative potency (%) with 95 % confidence limits of insulin of the invention compared to standard (HI).

Insulin analogue from Example#	Lipogenesis (potency rel to HI)
1	16.96
2	114.38
3	28.02
4	57.28
5	37.01
6	1.9
8	34.98
11	30.06
14	23.83
21	45.99
22	46.74
24	37.81
28	25.3
55	35.9
56	55.27
60	107.0
61	43.16
62	4.37
63	7.47

67	10.5
71	34.62
72	27.51
81	1.7
A14E, B25H, desB30 (prior art)	29.3
A14E, B16H, B25H, desB30 (prior art)	13.1

For the majority of the analogues according to the invention there is a good agreement between the obtained lipogenesis results and the insulin receptor binding results, thus confirming that the receptor binding is translated into receptor activation.

5

*Example 98 Guanidinium hydrochloride denaturation*

Guanidinium hydrochloride denaturation of selected insulin analogues containing extra disulfide bonds can be followed by circular dichroism (CD) spectroscopy in order to determine free energy of unfolding. Upon protein denaturation, negative CD in the far UV range (240-218-nm) gradually diminishes, consistent with the loss of ordered secondary structure that accompanies protein unfolding. The far-UV CD spectrum of human insulin is sensitive to both protein unfolding and self-association (Holladay et al., 1977 *Biochim. Biophys. Acta* 494, 245-254.; Melberg & Johnson, 1990, *Biochim. Biophys. Acta* 494, 245-254.). In order to separate these phenomena at pH 8, GuHCl titrations is carried out at different protein concentrations, e.g. 3, 37, and 250 µM. At these concentrations, insulin analogues exists mainly as monomers, dimers and mixture of dimers and higher aggregates. The insulin CD spectrum in the near UV range (330-250-nm) reflects the environment of the tyrosine chromophore with contributions from the disulfide linkages (Morris et al., 1968, *Biochim. Biophys. Acta.* 160, 145-155.; Wood et al., 1975, *Biochim. Biophys. Acta.* 160, 145-155.; Strickland & Mercola, 1976, *Biochemistry* 15, 3875-3884.). Plots of changes in molar ellipticities at both near UV and far UV regions as a function of denaturant concentration is be generated. Free energy of unfolding was previously calculated from such insulin denaturation curves fitted with two state model (Kaarsholm, N.C. et al 1993 *Biochemistry*, 32, 10773-8).

25 Protein concentrations is determined by UV absorbance and/or RP-HPLC and/or SEC-HPLC. Denaturation samples are prepared by combining different ratios of protein and

GuHCl stock solutions with 10 mM Tris/C104- buffer, pH 8.0. Protein stock solutions are typically 1.5 mM in 10 mM Tris/C104-, pH 8.0. GuHCl stock solutions are 8.25 M (determined by refractometry) in 10 mM Tris/C104-, pH 8.0. All CD spectra are recorded at 25°C. Far-UV CD denaturation samples are scanned from 250 to 218 nm. Typical cell path length and protein 5 concentrations are 0.2 cm and 37 pM, respectively. Near-UV CD denaturation samples are scanned from 330 to 250 nm using 1-cm path length and typically 75 pM protein. All spectra are smoothed by a Fourier transform algorithm before subtraction of the appropriate solvent blanks. In the far-UV range,  $\Delta\epsilon$  is based on the molar concentration of peptide bond, while in the near-UV  $\Delta\epsilon$  is normalized to the molar concentration of insulin monomer.

GuHCl denaturation curves are analyzed by assuming that the folding/unfolding transition is two-state, in which case equilibrium constants can be obtained at each denaturant concentration using  $K = (\Delta\epsilon_N - \Delta\epsilon)/(\Delta\epsilon - \Delta\epsilon_U)$ , where  $\Delta\epsilon$  is the observed value of the CD and  $\Delta\epsilon_N$  and  $\Delta\epsilon_U$  represent the CD values for native and unfolded forms, respectively, at the given GuHCl concentration (Pace, C. N. (1975) *CRC Crit. Rev. Biochem.* 3, 1-43.). Values for  $\Delta\epsilon_N$  and  $\Delta\epsilon_U$  at GuHCl concentrations in the transition region were obtained by linear extrapolation of the pre- and posttransition base lines into the transition region, i.e.,  $\Delta\epsilon_N = \Delta\epsilon^0_N + m_N[\text{GuHCl}]$  and  $\Delta\epsilon_U = \Delta\epsilon^0_U + m_U[\text{GuHCl}]$ , where  $\Delta\epsilon^0_N$  and  $\Delta\epsilon^0_U$  are intercepts and  $m_N$  and  $m_U$  are slopes of the pre- and posttransition base lines, respectively. The free energy of unfolding at a given denaturant concentration in the transition zone is given by  $\Delta G = -RT \ln K$ . We 10 assume a linear dependence of  $\Delta G$  on denaturant concentration:  $\Delta G = \Delta G_{H_2O} - m[\text{GuHCl}]$ , where  $\Delta G_{H_2O}$  is the value of  $\Delta G$  in the absence of denaturant and  $m$  is a measure of the dependence of  $\Delta G$  on denaturant concentration. Hence,  $\Delta G$  values derived from  $K$  in the transition zone may be extrapolated back to 0 M denaturant to give  $\Delta G_{H_2O}$ . The relationship between  $\Delta\epsilon$  and [GuHCl] for the complete unfolding curve is shown in eq 1 (Santoro, M. M., & 15 Bolen, D. W. (1988) *Biochemistry* 27, 8063-8068.):

$$\Delta\epsilon = \{(\Delta\epsilon^0_N + m_N[\text{GuHCl}]) + (\Delta\epsilon^0_U + m_U[\text{GuHCl}]) \exp[-(\Delta G_{H_2O} - m[\text{GuHCl}])/RT]\} / \{ (1 + \exp[-(\Delta G_{H_2O} - m[\text{GuHCl}])/RT]) \}$$

With  $\Delta\epsilon$  as the response and [GuHCl] as the independent variable, this equation is subjected to nonlinear least-squares analysis using, for example the NLIN procedure of PC 20 SAS (SAS Inc., Cary, NC). Six parameters then describe the denaturation curve:  $\Delta\epsilon^0_N$ ,  $\Delta\epsilon^0_U$ ,  $m_N$ ,  $m_U$ ,  $m$ , and  $\Delta G_{H_2O}$ . In addition, the GuHCl concentration at the midpoint of the denaturation curve,  $C_{\text{mid}}$ , is given by  $\Delta G_{H_2O}/m$ . The difference in the free energy of unfolding between human and mutant insulins may then be calculated from  $\Delta\Delta G_{H_2O} = \Delta G_{H_2O}(\text{mutant}) - \Delta G_{H_2O}(\text{wild type})$ .

*Example 99 Guanidinium hydrochloride denaturation*

An example of crystallization conditions is given below, however, the exact conditions could be different for different analogues and the optimal conditions are found by 5 screening many different conditions. Crystals are obtained by the sitting drop vapor diffusion method from, for example a reservoir solution containing 0.8 M K/NaTartrate, 0.1 M Tris pH 8.5, 0.5% PEG MME 5000. Data are collected with a rotating anode (Rigaku, MicroMax-007HF) equipped with a MarCCD detector and processed by XDS (J Appl Crystallogr 26: 795–800). The structure is solved by molecular replacement using Molrep (J Appl Crystallogr 10 30: 1022–1025.) with an in house structure as search model. Data refinement and model building is made using the programs Refmac (Acta Crystallogr D 53: 240–255.) and Coot (Acta Crystallogr D 60: 2126–2132.).

*Example 100 Size exclusion chromatography analysis of insulin*

15	Column	superose 12, 10/300GL column from GE healthCare
	Solvent flow	0.8 ml/min at ambient temperature (22 oC ± 1 oC).
	Running buffer	140 mM NaCl, 10 mM Tris/HCl pH 7.7
	Run time	30 min
	Standards	HSA (MW 66,5 kDa), insulin analogues of known sizes
20	Detection	276nm
	Sample	0.6 mM Insulin in neutral PO4 buffer
	Injection volume	50ul

Retention time of insulin analogue is determined. Insulin analogue's association state is determined by comparison to insulin analogues of known association properties. Insulin analogues with enhanced tendencies to be monomeric (minimized tendencies to form dimers) 25 are identified.

*Example 101 Near UV circular dichroism*

Near UV-CD spectroscopy at 276 nm is determined for a given insulin analogue in different concentrations (at least five concentrations in the range from ~1µM to ~10 mM). 30 The changes in the molar ellipticity at 276 nm are indicative of changes in the dimer interface. It is possible to assess insulin analogue's dimer formation tendencies by comparison to insulin analogues with known dimerization properties.



**CLAIMS**

1. An insulin analogue having two or more cysteine substitutions and at least one amino acid residue which is substituted with an amino acid which is not a cysteine, where the three di-

5 sulfide bonds of human insulin are retained, and

the sites of cysteine substitutions are chosen in such a way that the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin.

2. An insulin analogue according to claim 1, wherein the sites of cysteine substitutions are

10 chosen in such a way that

(1) the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin, and

(2) the human insulin analogue retains the desired biological activities associated with 15 human insulin.

3. An insulin analogue according to claim 1 or 2, wherein the sites of cysteine substitutions are chosen in such a way that

(1) the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds 20 not present in human insulin,

(2) the human insulin analogue retains the desired biological activities associated with human insulin, and

(3) the human insulin analogue has increased physical stability relative to human insulin and/or parent insulin

25 4. An insulin analogue according to any one of the preceding claims, wherein the sites of cysteine substitutions are chosen in such a way that

(1) the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human insulin,

30 (2) the human insulin analogue retains the desired biological activities associated with human insulin, and

(3) the human insulin analogue is stabilized against proteolytic degradation.

5. An insulin analogue according to any one of the preceding claims, wherein the amino acid residue in position A10 of the A-chain is substituted with a cysteine, the amino acid residue in

a position selected from the group consisting of B1, B2, B3 and B4 of the B-chain is substituted with a cysteine, and optionally the amino acid in position B30 is deleted.

6. An insulin analogue according to any one of the preceding claims, to the extend possible, wherein the amino acid residue in position A10 of the A-chain is substituted with a cysteine,

5 the amino acid residue in a position selected from the group consisting of B3 and B4 of the B-chain is substituted with a cysteine, and optionally the amino acid in position B30 is deleted.

7. An insulin analogue according to any one of the preceding claims, to the extend possible, wherein one or more additional disulfide bonds are obtained between the A-chain and the B-  
10 chain

8. An insulin analogue according to any one of the preceding claims, to the extend possible, which is selected from the group consisting of:

A10C, A14E, B1C, B16H, B25H, desB30 human insulin,

A10C, A14E, B1C, B25H, desB30 human insulin,

15 A10C, A14E, B2C, B16H, B25H, desB30 human insulin,

A10C, A14E, B2C, B25A, desB30 human insulin,

A10C, A14E, B2C, B25H, desB30 human insulin,

A10C, A14E, B3C, B16H, B25H, desB30 human insulin,

A10C, A14E, B3C, B25H, desB27, desB30 human insulin,

20 A10C, A14E, B3C, B25H, desB30 human insulin,

A10C, A14E, B3C, desB27, desB30 human insulin,

A10C, A14E, B4C, B16H, B25H, desB30 human insulin,

A10C, A14E, B4C, B25A, desB30 human insulin,

A10C, A14E, B4C, B25H, B28E, desB30 human insulin,

25 A10C, A14E, B4C, B25H, desB27, desB30 human insulin,

A10C, A14E, B4C, B25H, desB30 human insulin,

A10C, A14E, B4C, B25N, B27E, desB30 human insulin,

A10C, A14E, B4C, B25N, desB27, desB30 human insulin,

A10C, A14E, desB1, B4C, B25H, desB30 human insulin,

30 A10C, A14H, B4C, B25H, desB30 human insulin,

A10C, B3C, B25H, desB27, desB30 human insulin,

A10C, B3C, B25H, desB30 human insulin,

A10C, B4C, B25H, desB27, desB30 human insulin,

A10C, B4C, B25H, desB30 human insulin,

35 A10C, A14E, B1C, B16H, B25H, desB30 human insulin,

A10C, A14E, B2C, B16H, B25H, desB30 human insulin,  
A10C, A14E, B3C, B16H, B25H, desB30 human insulin, and  
A10C, A14E, B4C, B16H, B25H, desB30 human insulin.

9. An insulin analogue according to any one of the preceding claims, to the extend possible,

5 which is selected from the group consisting of:

A10C, A21G, B1G, B3C, B27E, desB30 human insulin

A10C, A21G, B1G, B3E, B4C, B27E, desB30 human insulin

A10C, A21G, B2C, B3E, B27E, B28K, desB29, desB30 human insulin

A10C, A21G, B2C, B3E, B28E, desB30 human insulin

10 A10C, A21G, B3C, B27E, B28K, desB29, desB30 human insulin

A10C, A21G, B3C, B28E, desB30 human insulin

A10C, A21G, B3E, B4C, B22E, B28E, desB30 human insulin

A10C, A21G, B3E, B4C, B27E, B28K, desB29, desB30 human insulin

A10C, A21G, B3E, B4C, B28E, desB30 human insulin

15 A10C, A21G, B3E, B4C, desB24, B28E, desB30 human insulin

A10C, A21G, B3K, B4C, B28E, desB30 human insulin

A10C, A21G, B3Q, B4C, B28D, desB30 human insulin

A10C, A21G, B3Q, B4C, B28E, desB30 human insulin

A10C, A21G, B4C, B28E, desB30 human insulin

20 A10C, A21G, B4C, desB30 human insulin

A10C, A21G, desB1, B2C, B3E, B27E, B28K, desB29, desB30 human insulin

A10C, A21G, desB1, B2C, B3E, B28E, desB30 human insulin

A10C, A21G, desB1, B3C, B27E, B28K, desB29, desB30 human insulin

A10C, A21G, desB1, B3C, B27E, desB30 human insulin

25 A10C, A21G, desB1, B3C, B28E, desB30 human insulin

A10C, A21G, desB1, B3E, B4C, B27E, B28K, desB29, desB30 human insulin

A10C, A21G, desB1, B3E, B4C, B28E, desB30 human insulin

A10C, A21G, desB1, B3Q, B4C, B28E, desB30 human insulin

A10C, A22K, B3C, desB27, desB30 human insulin

30 A10C, B1C, B28D, desB30 human insulin

A10C, B2C, B28D, desB30 human insulin

A10C, B2C, B3A, desB30 human insulin

A10C, B2C, B3D, desB30 human insulin

A10C, B2C, B3E, desB30 human insulin

35 A10C, B2C, B3F, desB30 human insulin

A10C, B4C, B28D human insulin, and  
A10C, B4C, B28D, desB30 human insulin

10. A method for stabilizing an insulin comprising substituting two or more amino acids of  
human insulin or desB30 human insulin with cysteine residues and at least one amino acid  
5 residue with an amino acid which is not a cysteine, wherein

- a. the three disulfide bonds of human insulin are retained and
- b. the sites of cysteine substitutions are chosen in such a way that the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds not present in human

10 insulin,

thereby creating an insulin analogue comprising one or more additional disulfide bonds not present in human insulin.

11. A pharmaceutical composition comprising a biologically active amount of the insulin analogue according to any of the claims 1-9 and a pharmaceutically acceptable carrier.

15 12. A method for the treatment of diabetes mellitus in a subject comprising administering to a subject an insulin analogue according to any of the claims 1-9 or a pharmaceutical composition according to claim 11.

13. An insulin analogue according to any of the claims 1-9 for use as a pharmaceutical in the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance and  
20 type 1 diabetes.

14. A nucleic acid sequence encoding an insulin analogue according to any of the claims 1-9, a derivative thereof, a partial sequence thereof, a degenerated sequence thereof or a sequence which hybridises thereto under stringent conditions.

15. A process for preparing a pharmaceutical composition according to claim 11 comprising  
25 mixing an insulin analogue according to any of the claims 1-9 with pharmaceutically acceptable substances and/or excipients.






Fig. 1/3

**Fig. 2/3**



**Fig. 3/3**

# INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2011/060382

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. C07K14/62  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BRANGE J ET AL: "Insulin structure and stability", PHARMACEUTICAL BIOTECHNOLOGY, KLUWER, DORDRECHT, NL, vol. 5, 1 January 1993 (1993-01-01), pages 315-350, XP002467249, ISSN: 1078-0467 *Whole document*</p> <p>-----</p> <p style="text-align: center;">-/-</p>	1-15

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

19 September 2011

10/10/2011

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Bulcao de Melo B., T

## INTERNATIONAL SEARCH REPORT

International application No PCT/EP2011/060382
---

## C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BREMS D N ET AL: "IMPROVED INSULIN STABILITY THROUGH AMINO ACID SUBSTITUTION", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 5, no. 6, 1 September 1992 (1992-09-01), pages 519-525, XP000306021, ISSN: 0269-2139 *Whole document, in particular: Abstract and table II* -----	1-15
A	WO 92/00321 A1 (NOVO NORDISK AS [DK]) 9 January 1992 (1992-01-09) *Whole document, in particular: Abstract, tables I, II and III and claims* -----	1-15
A	WO 2007/135117 A2 (NOVO NORDISK AS [DK]; OLSEN HELLE BIRK [DK]; KAARSHOLM NIELS CHRISTIAN) 29 November 2007 (2007-11-29) *Whole document, in particular: Abstract, page 6, line 17 - page 12, line 19* -----	1-15
A	WO 2010/066636 A1 (NOVO NORDISK AS [DK]; STIDSEN CARSTEN ENGGAARD [DK]; GLENDORF TINE [DK]) 17 June 2010 (2010-06-17) *Whole document, in particular: Abstract and claims* -----	1-15

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2011/060382

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:



**Box No. III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
  3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
  - The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
  - No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 1-4, 7, 10-15(all partially)

Claim 1 refers to an insulin analogue having two or more cysteine substitutions and at least one amino acid residue which is substituted with an amino acid which is not a cysteine. The subject-matter of claim 1 is not clearly characterized because the sites of said cysteine substitutions are defined merely by reference to a result to be achieved, namely the sites of cysteine substitutions are chosen in such a way that the introduced cysteine residues are placed in the three dimensional structure of the folded insulin analogue to allow for the formation of one or more additional disulfide bonds, contrary to the requirements of clarity of Article 6 PCT. The result-to-be-achieved type of definition does not allow the scope of the claim to be ascertained. The fact that any insulin analogue could be tested to check whether it has said desired features, does not overcome this objection, as the skilled person would not have knowledge beforehand as to whether it would fall within the scope claimed, except for the human insulin analogues identified in claims 5, 6, 8 and 9 and in the description (pages 11-14 and examples). Undue experimentation would be required to test human insulin analogues randomly. Moreover, it should be noted that claim 1 relates to an extremely large number of possible insulin analogues. Support and disclosure in the sense of Article 5 and 6 PCT is to be found however for only a small number of human insulin analogues claimed (see claims 5, 6 and 8 and the description). Claims 2-4, which depend on claim 1, further define the insulin analogue merely by indicating further results to be achieved, namely retaining the desired biological activities, having increased physical stability and being stabilized against proteolytical degradation. The non-compliance with the substantive provisions is to such an extent, that a meaningful search over the whole of the claimed subject-matter impossible. Consequently, the search of claims 1-4, and of all the claims relating to said claims (claims 7 and 10-15) was restricted to those insulin analogues which appear to be clear, supported and disclosed, namely the insulin analogues as defined in claims 5, 6, 8 and 9 and in the description.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.2), should the problems which led to the Article 17(2) declaration be overcome.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No

PCT/EP2011/060382

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9200321	A1 09-01-1992	AU 8054391	A 23-01-1992	A
		EP 0536245	A1 14-04-1993	
		IE 912247	A1 01-01-1992	
		JP 5508406	T 25-11-1993	
		NZ 238718	A 25-06-1992	
		PT 98124	A 30-04-1992	
		ZA 9104830	A 25-03-1992	
-----	-----	-----	-----	-----
WO 2007135117	A2 29-11-2007	NONE		
-----	-----	-----	-----	-----
WO 2010066636	A1 17-06-2010	NONE		
-----	-----	-----	-----	-----